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Jiyoon Lee 
TUMOR-STROMA INTERACTION MEDIATED BY TISSUE 
TRANSGLUTAMINASE IN PANCREATIC CANCER 
Pancreatic ductal adenocarcinoma (PDA) is a deadly disease due to early 
metastasis and resistance to chemotherapy.  PDA is commonly associated with a 
dense desmoplastic stroma, which forms a protective niche for cancer cells.  
Tissue transglutaminase (TG2), a Ca2+-dependent enzyme, is abundantly 
expressed in pancreatic cancer cells and crosslinks proteins through acyl-
transfer transamidation between glutamine and lysine residues.  The objective of 
the study was to determine the functions of TG2 in the pancreatic stroma.  
Orthotopic pancreatic xenografts and co-culture systems tested the mechanisms 
by which the enzyme modulates tumor-stroma interactions.  We showed that 
TG2 secreted by cancer cells is enzymatically active and renders the stroma 
denser by crosslinking collagen, which in turn activates fibroblasts and stimulates 
their proliferation.  Yes-associated protein (YAP) and transcriptional co-activator 
with PDZ-binding motif (TAZ) are transcription factors involved in 
mechanotransduction.  The TG2-mediated fibrosis-rich, stiff microenvironment 
conveys mechanical cues to cancer cells leading to activation of YAP and TAZ, 
promoting cell proliferation and tumor growth.  Stable knockdown of TG2 in 
pancreatic cancer cells led to decreased size of pancreatic xenografts and 
increased sensitivity of xenografts to gemcitabine.  Taken together, our results 
demonstrate that TG2 secreted in the tumor microenvironment orchestrates the 
crosstalk between cancer cells and the stroma, fundamentally impacting tumor 
viii 
growth and response to chemotherapy.  Our study supports TG2 inhibition in the 
pancreatic stroma as a novel strategy to block pancreatic cancer progression. 
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CHAPTER 1.  INTRODUCTION 
1.1.  Pancreatic ductal adenocarcinoma 
Pancreatic ductal adenocarcinoma (PDA), originating in the pancreatic 
ductal epithelium, is the fourth leading cause of cancer mortality in the world with 
a 5-year survival rate of less than 7% (R. L. Siegel, Miller, & Jemal, 2015).  Most 
PDA patients are diagnosed at an advanced stage with only 10-15% patients 
being candidates for curative surgical resection (Sultana, Cox, Ghaneh, & 
Neoptolemos, 2012).  This late diagnosis is due to the rapid tumor growth and 
metastatic propensity, lack of sensitive early screening biomarkers, and 
resistance to chemotherapy and radiation (Feig et al., 2012; Willett, Czito, 
Bendell, & Ryan, 2005).  Currently approved drugs including gemcitabine and 
erlotinib induce a modest increase in patient survival, but do not cure the disease 
(Burris et al., 1997; Moore et al., 2007). 
The cause of PDA is multifactorial including smoking, family history of 
chronic pancreatitis, diabetes, obesity, blood type, advanced age, and male sex 
(Klein et al., 2004; Raimondi, Maisonneuve, & Lowenfels, 2009; Wolpin et al., 
2009).  Among these risk factors, smoking (~20%) and family history (~10%) are 
the most influential causes (Blackford et al., 2009; Petersen et al., 2006).  In 
addition, PDA tumors from smokers contain more genetic mutations than those 
from non-smokers (Blackford et al., 2009). 
The exact cell type that gives rise to PDA is not yet known.  In recent 
years, however, PDA is thought to arise from non-invasive precursor lesions and 
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progress to invasive adenocarcinomas through a series of hyperplastic and 
dysplastic ductal lesions termed pancreatic intraepithelial neoplasia (PanIN;  
Figure 1) (Hezel, Kimmelman, Stanger, Bardeesy, & Depinho, 2006; Ralph H. 
Hruban, Wilentz, & Kern, 2000; Vincent, Herman, Schulick, Hruban, & Goggins, 
2011).  The PanIN progresses through three different stages, PanIN-1 (PanIN-1A 
and PanIN-1B), PanIN-2, and PanIN-3, in an order of increasing cytological 
atypia with genetic aberrations.  Early stage of PanIN (PanIN-1) often harbors 
KRAS oncogene mutations; KRAS and CDKN2A/p16 tumor suppressor 
mutations are present in the intermediate stage (PanIN-2); and nuclear atypia 
and mitotic phenotype with p53 tumor suppressor mutations are present (PanIN-
3) as PanIN progresses to pancreatic carcinoma (Feig et al., 2012; R. H. Hruban 
et al., 2006; Li, Xie, Wolff, & Abbruzzese, 2004). 
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Figure 1.  Progression model for PDA.  PDA is appreciated to develop through a series 
of hyperplastic and dysplastic lesions termed pancreatic intraepithelial neoplasia 
(PanIN).  Mutations of the oncogene (KRAS) and tumor suppressors (INK4, p16, p53, 
SMAD4) take place in the progression from normal to malignant epithelium.  Figure is 
modified from “Progression model for pancreatic cancer” by R. Hruban, M. Goggins, J. 
Parsons, and S. Kern, 2000, Clinical Cancer Research, 6, p. 2969-72 © 2000 American 
Association for Cancer Research. 
 
 
 
 
KRAS is a GTPase, which regulates growth factor signaling and activates 
multiple downstream signaling cascades involved in cellular proliferation, 
survival, and differentiation (Campbell, Khosravi-Far, Rossman, Clark, & Der, 
1998).  Mutation of KRAS is the most common genetic alteration observed in 
PDA cases (≥ 90%) and represents a gain-of-function mutation of glycine 12 to 
aspartate at codon (G12D) (Nakanishi & Toi, 2005).  Several studies have 
reported that KRAS mutations are also a marker of poor prognosis in PDA 
patients (Ghosh, May, & Kopp, 1998; Witkiewicz et al., 2015).  Most PDA tumors, 
which have mutational activation of KRAS, overexpress growth factors and 
cytokines and have lost activation of tumor suppressor genes including 
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CDKN2A/p16 and p53 (Kanda et al., 2012).  Combination of these abnormalities 
activates downstream signaling pathways of KRAS, such as Src, nuclear factor-
kB (NF-kB), and Stat pathways resulting in cancer cell proliferation, tumor 
growth, and metastasis. 
A recent analysis of the genetic diversity of PDA used a whole-exome 
sequencing approach in 109 PDA specimens (Witkiewicz et al., 2015).  Tumors 
with higher chromosomal instability harbored mutations in DNA break repair 
genes and were associated with poor prognosis.  Overexpression of MYC was 
observed in the adenosquamous subtype of PDA and in PanIN-2, suggesting its 
role in initiation and progression of PDA.  RBM10, a regulator of alternative 
splicing (Inoue et al., 2014), was found to be mutated in the aggressive PDA.  On 
the other hand, mutation in ARID1A, a chromatin remodeling gene (Helming et 
al., 2014), was related with poor survival.  In addition, even though mutation of 
KRAS, mostly on codon 12, is an indicator of poor prognosis, mutation on codon 
61 was identified to lead to lesser activation of ERK and to be associated with 
improved survival, suggesting diverse consequences of KRAS mutations in PDA 
(Biankin et al., 2012; Ihle et al., 2012; Jones et al., 2008).  BRAF V600E mutation 
was found to be mutually exclusive with KRAS mutations, and led to sensitivity to 
BRAF inhibitors, such as vemurafenib, in PDA models.  In addition, alterations in 
the TGF-β, Wnt/β-catenin, NOTCH, Hedgehog, and RB pathways, chromatin 
remodeling, and DNA repair have been identified (Witkiewicz et al., 2015).  
These recent data provide a more detailed molecular landscape of pancreatic 
tumors. 
   5 
1.2.  PDA Stroma 
 A unique hallmark of PDA is the dense desmoplastic stroma (DS) (Feig et 
al., 2012; Korc, 2007).  The activated DS is heterogenous and composed of 
fibroblasts, pancreatic stellate cells (PSCs), endothelial cells, immune cells, 
nerve cells, extracellular matrix (ECM), cytokines and growth factors, and other 
cellular components (Karin, Cao, Greten, & Li, 2002; Korc, 2007; Wang et al., 
1999).   The DS is dynamic, and its composition changes constantly during the 
progression from early stage PanIN to aggressive PDA (Figure 2) (Feig et al., 
2012).  Cytokines and growth factors secreted into the PDA tumor 
microenvironment (TME) include the transforming growth factor-beta (TGF-β), 
the platelet-derived growth factor (PDGF), the epidermal growth factor (EGF), the 
vascular endothelial growth factor (VEGF), and interleukin-1 and -6 (IL-1 and IL-
6), all of which activate stromal cells (Maehama & Dixon, 1998; Tamura et al., 
1998; J. Zhao & Guan, 2009). 
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Figure 2.  Changes of the PDA stroma composition during the progression from early 
stage PanIN to aggressive PDA.  As tumorigenesis progresses, vasculature, collagen 
production, and immune cell recruitment increases in the tumor microenvironment, 
resulting in formation of the dense desmoplastic stroma.  Figure is modified from “The 
role of inflammatory cells in fostering pancreatic cancer cell growth and invasion” by A. 
Evans and E. Costello, 2012, Frontiers in physiology, 3, p. 270 © Evans and Costello. 
 
 
 
 
PSCs are the most prominent fibroblastic cells in the DS and are activated 
by stimulants secreted in the tumor milieu by PDA cells and proliferate rapidly 
(Karin et al., 2002; Maehama & Dixon, 1998).  Activated myofibroblasts and 
PSCs produce and secrete ECM proteins including collagen I and III, fibronectin, 
matrix metalloproteinases (MMPs), and other matrix proteins into the TME 
(Mizushima, 2007; Rossin et al., 2014; J. Zhao & Guan, 2009).  These proteins 
remodel the ECM and interact with PDA cells leading to increased tumorigenicity 
and metastatic potential (Willett et al., 2005).  All the components in the PDA 
TME (cells and ECM components) interact with each other through autocrine and 
paracrine mechanisms to induce formation of the dense DS (Wang et al., 1999).  
This heterotypic interaction provides a supportive TME for survival and 
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progression of PDA, protecting cancer cells from environmental stress including 
chemo- and radiotherapy (D. Hanahan & Weinberg, 2011).  In addition, PSCs 
expressing CD10 surface marker secrete elevated levels of MMP-3 and promote 
invasion and tumor growth (Ikenaga et al., 2010; Wilson, Pirola, & Apte, 2014). 
The ECM of the pancreatic DS is prominently composed of collagens, 
non-collagen glycoproteins, growth factors, and modulators of the cell-matrix 
interaction (Feig et al., 2012; Karin et al., 2002).  The alterations of ECM protein 
composition determine the invasion and migration ability of PDA cells (Grzesiak 
& Bouvet, 2006).  Collagen I, III, and fibronectin are the major components of the 
pancreatic DS (Gress et al., 1995; Lunardi, Muschel, & Brunner, 2014; Wang et 
al., 1999).  It has been reported that alterations of collagen deposition or 
degradation are involved in cell-survival and migration of PDA cells, and that 
adhesion of PDA cells to fibronectin, collagen I, IV, and laminin decreases their 
sensitivity to anticancer drugs (Ohlund, Franklin, Lundberg, Lundin, & Sund, 
2013; Shields, Dangi-Garimella, Krantz, Bentrem, & Munshi, 2011; J. Zhao & 
Guan, 2009).  Therefore, the increased expression of these ECM proteins may 
correlate with PDA resistance to chemotherapy. 
Vasculature and angiogenesis are recognized hallmarks of tumorigenesis 
(Douglas Hanahan & Weinberg, 2000).  However, in PDA, blood microvessel 
density (MVD) is lower than in normal pancreas and the vasculature is 
disorganized, so that the partial pressure of oxygen is low, leading to hypoxia 
(Erkan et al., 2012).  The lack of vasculature in the pancreatic tumors is inversely 
correlated with elevated expression of angiogenic factors including VEGF, 
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cyclooxygenase-2 (COX-2), and neuropilin-1 (NRP-1) (Fukahi, Fukasawa, 
Neufeld, Itakura, & Korc, 2004; Haixia, Qikui, Liuping, & Li, 2005; Hlatky, 
Hahnfeldt, & Folkman, 2002).  The vasculature of PDA tumors develops in 
coordination with inflammatory and stromal cell accumulation (Lunardi et al., 
2014).  For example, it has been reported that the activation of CXCR2, an IL-8 
receptor that mediates neutrophil migration to inflammation sites, increases 
angiogenesis by promoting connective tissue growth factor (CTGF) secretion by 
stromal cells (Ijichi, 2012).  On the other hand, overexpression of sonic hedgehog 
(SHH) by neoplastic cells in PDA during inflammation and neoplasia promotes 
desmoplasia while decreasing vasculature (Kenneth P Olive et al., 2009). 
The hypo-vascular and hypoxic dense stroma is presumed to be less 
permeable to chemotherapy, protecting PDA cells from environmental stress 
(Miyamoto et al., 2004; K. P. Olive et al., 2009).  Related to this perspective, a 
recent study using clinical PDA specimens demonstrated that the delivery of 
gemcitabine into human pancreatic tumors is highly heterogenous and strongly 
correlated with the existing stromal reaction (Koay, Baio, et al., 2014; Koay, Truty, 
et al., 2014).  In addition, Olive et al. have proposed that the altered vascularity 
and vascular architecture of PDA tumors to impaired drug delivery and 
penetration (K. P. Olive et al., 2009).  Improved delivery of gemcitabine can be 
achieved by inhibiting the hedgehog (Hh) pathway, resulting in the depletion of 
PDA stroma (K. P. Olive et al., 2009).  KPC mice, which conditionally express 
mutated KRAS and p53 alleles and form PDA tumors, were used for that 
investigation.  The KPC mice were given IPI-926, a Smoothened (Smo; Hh 
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signaling mediator) inhibitor, daily.  Treatment resulted in modification of the 
stroma; decreased collagen I content and reduced proliferation of α-smooth 
muscle actin (α-SMA)+ myofibroblasts.  Moreover, inhibition of Hh pathway 
increased angiogenesis and proliferation of endothelial (CD31+) cells.  KPC mice 
treated with IPI-926 had tumors with increased microvessel density (MVD) and 
displayed more effective delivery of gemcitabine into tumors, as evidenced by 
elevated gemcitabine metabolites and increased apoptotic tumor cells.  KPC 
mice treated with the combination of IPI-926 and gemcitabine also showed 
extended median survival from 11 days to 25 days, decreased tumor burden, and 
reduced metastases (K. P. Olive et al., 2009). 
In contrast to this study, two other recent reports have suggested the 
opposite concept, specifically, that the inhibition of some stroma components 
may enhance cancer cell invasion, tumor growth, and metastasis (Gore & Korc, 
2014; Ozdemir et al., 2014; Rhim et al., 2014).  Rhim et al. used conditional Shh 
knockout mice and IPI-926 administration to suppress stroma (Rhim et al., 2014).  
Attenuation of stroma formation by using a Shh knockout or by using IPI-926 
treatment led to undifferentiated PDA, increased metastasis, and decreased 
survival.  Özdemir et al. used a transgenic mouse model which lacks α-SMA+ 
myofibroblasts in the pancreas (Ozdemir et al., 2014).  Depletion of α-SMA+ 
myofibroblasts led to undifferentiated, invasive PDA tumors with enhanced 
hypoxia, epithelial-to-mesenchymal transition (EMT), and increased number of 
cancer stem cells, which led to reduced survival of the mice.  One important 
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difference between the previous and these two latter studies was the length of 
the observation period (weeks; 2009 study vs. months; 2014 studies). 
Taken together, these studies suggest that the PDA stroma is composed 
of diverse components and affected by a complex interplay between the 
components.  Therefore, targeting stroma can enable tumors to respond more 
efficiently to chemotherapy, but also can lead to enhanced proliferation of cancer 
cells enabling tumors to become more aggressive.  Moreover, even though the 
experimental models, genetically engineered mouse models and orthotopic 
xenograft mouse models, mimic human tumors, the biological circumstances 
may vary.  For example, the proportion of stroma and diversity of components in 
mouse-derived tumors is significantly less than that observed in human tumors.  
Therefore, further studies are necessary to more clearly delineate characteristics 
and functions of PDA stroma, using both in vitro, murine and human specimen 
based analyses. 
 
1.3.  Chemotherapy 
1.3.1.  Gemcitabine 
Gemcitabine (difluorodeoxycytidine; dFdC) is a novel nucleoside analog, 
which has a wide range of antitumor activity and is a standard treatment for 
several cancers, including PDA (Burris et al., 1997; Hertel et al., 1990). 
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To become active, gemcitabine undergoes intracellular phosphorylation by 
deoxycytidine kinase, resulting in the accumulation of difluorodeoxycytidine 
triphosphate (dFdCTP) within cells.  dFdCTP competes with deoxycytidine 
triphosphate (dCTP) for incorporation into DNA, which results in inhibition of DNA 
synthesis (Huang, Chubb, Hertel, Grindey, & Plunkett, 1991).  Moreover, 
gemcitabine presumably inhibits ribonucleotide reductase, which reduces 
intracellular deoxynucleoside triphosphate pools, and deoxycytidine 
monophosphate (dCMP) deaminase, which is responsible for gemcitabine 
degradation (Gandhi & Plunkett, 1990). 
Advanced pancreatic cancer patients who received gemcitabine showed 
improved symptoms compared to those who received 5-fluorouracil (5-FU), 
which was the most commonly used agent for PDA prior to the gemcitabine 
(Burris et al., 1997).  Clinical benefit was determined by monitoring pain, 
performance status, and weight of the patients.  Even though patients receiving 
gemcitabine experienced clinical benefit, there was no significant effect on 
survival.  Thus, gemcitabine improves quality of life but does not cure the disease 
or prolong survival (Seufferlein, Bachet, Van Cutsem, Rougier, & Group, 2012). 
Some studies have suggested that gemcitabine-based cytotoxic 
combinations have a significant benefit in patients with good performance status 
(Cunningham et al., 2009; Heinemann, Boeck, Hinke, Labianca, & Louvet, 2008; 
Locher et al., 2008).  Recent studies, therefore, are focusing on combination 
therapy of gemcitabine with other cytotoxic or biologic agents including erlotinib 
and nab-paclitaxel (Moore et al., 2007; Von Hoff et al., 2011).  
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1.3.2.  Erlotinib 
Erlotinib is an approved oral human epidermal growth factor receptor type 
1 (HER1/EGFR) tyrosine kinase inhibitor for non-small-cell lung cancer patients 
(Rich & Whittaker, 2005).  Pancreatic tumors often overexpress HER1/EGFR, 
which is an indicator of poor prognosis and disease progression (Akar et al., 
2007; Cheung et al., 2008; Iacobuzio-Donahue et al., 2003).  It has been 
reported that inhibition of HER1/EGFR tyrosine kinase signaling decreases the 
growth and metastasis of human pancreatic tumor xenografts and improves the 
anticancer effects of gemcitabine (D.-S. Kim, Park, Nam, Kim, & Kim, 2006; 
Mann et al., 2006). 
Randomly assigned patients who received combination therapy of 
gemcitabine and erlotinib showed improved overall survival by 2 weeks and 
improved progression-free survival compared to those who received only 
gemcitabine (Moore et al., 2007).  However, the patients on the erlotinib and 
gemcitabine combination therapy experienced more toxicity including rash, 
diarrhea, infection, stomatitis, protocol-related death, and interstitial lung disease 
(ILD)-like syndrome.  Interestingly, the occurrence of rash was associated with 
better outcome and longer survival. 
1.3.3.  Nab-paclitaxel 
Nab-paclitaxel (Abraxane), an albumin-bound paclitaxel formulation, has 
antitumor activity as a single agent and synergistic activity in combination with 
gemcitabine in pancreatic cancer mouse models (Frese et al., 2012; Von Hoff et 
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al., 2011).  It has been suggested that nab-paclitaxel binds to the secreted 
protein acidic and rich in cysteine (SPARC), overexpressed in the PDA stroma, 
and facilitates increased delivery of chemotherapeutic agents to tumors (R. H. 
Hruban & Klimstra, 2014; Infante et al., 2007; Von Hoff et al., 2013). 
According to Von Hoff et al. (Von Hoff et al., 2013), PDA patients who 
received the combination of gemcitabine and nab-paclitaxel had significantly 
improved median overall survival from 6.7 months (gemcitabine alone) to 8.5 
months (combination of gemcitabine and nab-paclitaxel), progression-free 
survival, and response rate compared to gemcitabine single treatment.  However, 
the gemcitabine-nab-paclitaxel combination also increased the rates of peripheral 
neuropathy and myelosuppression.  At present time, the combination of 
gemcitabine and nab-paclitaxel has become a new standard treatment for 
patients with advanced stage PDA (Hidalgo et al., 2015). 
1.3.4.  FOLFIRINOX 
FOLFIRINOX is a combination chemotherapy regimen, composed of 5-
FU, oxaliplatin, irinotecan, and leucovorin (Ychou, 2003).  Oxaliplatin has clinical 
activity against pancreatic cancer only when combined with 5-FU (Ruiz, Del 
Valle, & Gomez, 2004).  Irinotecan also has some clinical activity against 
advanced pancreatic cancer, and is synergistic when administered before 5-FU 
and leucovorin (Azrak et al., 2004; Pavillard et al., 1998).  In addition, an in vitro 
experiment showed that oxaliplatin and irinotecan have synergistic activity 
(Zeghari-Squalli, Raymond, Cvitkovic, & Goldwasser, 1999). 
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Conroy et al. performed phase 2-3 studies comparing FOLFIRINOX and 
gemcitabine in patients with PDA (Conroy et al., 2011).  The FOLFIRINOX 
treated group showed improved median overall survival by 4 months and 
improved progression-free survival and response rate compared to the 
gemcitabine group.  However, adverse events, such as febrile neutropenia and 
deterioration of quality of life, occurred more frequently in the FOLFIRINOX 
group compared to the gemcitabine group.  FOLFIRINOX provides survival 
advantage, but is more toxic than gemcitabine, thus its use may be limited to 
relatively younger patients with good performance status (Conroy et al., 2011; 
Hidalgo et al., 2015). 
1.3.5.  Summary of current treatments 
 At current time, ‘gemcitabine and nab-paclitaxel’ or ‘FOLFIRINOX’ are 
offered to patients with advanced PDA and good performance status.  Single 
agent gemcitabine remains a reasonable option for more debilitated patients. 
 
1.4.  Transglutaminase 
1.4.1.  Transglutaminase family 
The human transglutaminases (TGases) are a protein family that consists 
of protein 4.2, factor XIII-A (FXIII-A), and TG1-7 (Griffin, Casadio, & Bergamini, 
2002) (Table 1 and Figure 3).  Protein 4.2 lacks catalytic activity and is restricted 
to erythrocytes (Lorand & Graham, 2003).  FXIII-A and TG1-7, produced as 
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zymogens, are enzymes that catalyze Ca2+-dependent post-translational 
modifications.  FXIII-A is involved in wound healing where it stabilizes fibrin clots 
(Iismaa, Mearns, Lorand, & Graham, 2009).  TG1 is a keratinocyte TGase that is 
involved in keratinocyte differentiation.  TG2 is a tissue TGase, which will be 
discussed in detail in the next section.  TG3 is an epidermal TGase involved in 
skin maturation, and TG4 is a prostatic secretory TGase, which is important for 
sperm maturation. TG5, also called TGx, is involved in cornified envelope 
assembly and keratinocyte differentiation. TG6 and TG7 are also named as TGy 
and TGz, respectively, but have not been well characterized to date (Griffin et al., 
2002; Lorand & Graham, 2003). 
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Table 1.  TGase family members; expressions, localizations, encoding genes, and 
related diseases. 
 
Proteins 
Tissue 
Expression 
Localization Gene 
Related 
Biology 
FXIIIA 
Platelets, 
Astrocytes, 
Placenta, 
Plasma 
Cytosol, 
Extracellular F13A1 
Blood 
coagulation 
TG1 
Keratinocytes, 
Brain 
Cytosol, 
Membrane TGM1 
Keratinocyte 
differentiation 
TG2 Ubiquitous 
Cytosol, Nucleus, 
Membrane, 
Extracellular 
TGM2 Multiple 
TG3 
Squamous 
epithelium, 
Brain 
Cytosol TGM3 
Cornified 
envelope (CE) 
formation 
TG4 Prostate Unknown TGM4 Semen coagulation 
TG5 Ubiquitous Unknown TGM5 
CE formation, 
Keratinocyte 
differentiation 
TG6 Unknown Unknown TGM6 Unknown 
TG7 Ubiquitous Unknown TGM7 Unknown 
Band 4.2 
Red blood cells, 
Bone marrow, 
Fetal liver and 
spleen 
Membrane EBP42 
Erythrocyte 
membrane 
integration, 
Hereditary 
spherocytosis 
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Figure 3.  Cellular distribution and possible functions of TGases.  TGases can localize 
on membrane (e.g. TG1), in cytoplasm and nucleus (e.g. TG2), and in extracellular 
compartment (Factor XIIIa).  Figure is modified from “Tissue transglutaminase: an 
enzyme with a split personality” by J.Chen and K. Mehta, 1999, The International 
Journal of Biochemistry and Cell Biology, 31, p. 817-36 © 1999 Elsevier Science Ltd. 
 
 
 
 
TGase family members have a conserved structure with four distinct 
domains: an N-terminal β-sandwich domain, a catalytic domain, and two C-
terminal β-barrel domains (Mehta, Kumar, & Kim, 2010) (Figure 4).  The catalytic 
core domain of TGases contains a catalytic triad (Cys277, His335, and Asp358), 
essential residues for catalysis.  Band 4.2 is catalytically inactive because it lacks 
the required cysteine residue in the catalytic triad (Figure 4). 
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Figure 4.  Schematic illustration of TGase domains.  TGases are consisted of 4 distinct 
domains; a N-terminal β-sandwich domain, an α/β catalytic core domain containing 
Cys277, His335, and Asp358 catalytic triad, and 2 C-terminal β-barrel domains. 
 
 
 
 
The post-translational reactions catalyzed by TGs can be separated into 
three reactions (Figure 5): transamidation (crosslinking, amine incorporation, and 
acylation), hydrolysis (deamination and isopeptide cleavage), and esterification.  
Transamidation causes (a) protein crosslinking by forming a ε-(γ-glutamyl)-lysine 
isopeptide bond between the lysine residue of one donor protein and the 
glutamine residue of another acceptor protein; (b) amine incorporation of an 
amine into the glutamine residue of the acceptor protein; and (c) acylation of a 
lysine side chain of the donor protein.  Hydrolysis and esterification are caused 
via the direct attack of γ-amides of glutamine residues by water and alcohol 
each.  The first TGase enzyme, TG2, was identified based on its ability to 
catalyze amine incorporation into proteins.  Ca2+-dependent amine incorporation 
remains the major modality of detecting TG2 activity (Griffin et al., 2002; Liu, 
Cerione, & Clardy, 2002; Mehta et al., 2010). 
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Figure 5.  Catalytic activity of TGases.  TGases catalyze Ca2+-dependent reactions; 
transamidation, hydrolysis, and esterification.  Glutamine-containing protein or peptide is 
the major substrate of TGases and reacts with 1) a lysine-containing protein or peptide 
to cause crosslinking of the 2 substrates, with 2) a polyamine to cause amine 
incorporation into the glutamine-containing protein or peptide, with 3) H2O to cause 
deamidation, and with 4) alcohol to cause esterification.  Figure is modified after 
“Transglutaminases: Nature’s biological glues” by M. Griffin, R. Casadio, and C. 
Bergamini, 2002, The Biochemical Journal, 368, p.377-396 © 2002 Biochemical Society. 
 
 
 
 
1.4.2.  Tissue transglutaminase 
TG2 is a multifunctional protein with a molecular weight of 78kDa.  TG2 is 
encoded by TGM2 on human chromosome 20q11-12 and is composed of 13 
exons and 12 introns (Iismaa et al., 2009; Mehta et al., 2010).  TG2 is 
distinguished from other TGs by its unique characteristics which include 
ubiquitous expression, multi-compartmental cellular localization, and binding to 
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and hydrolysis of guanine nucleotides (Lorand & Graham, 2003).  Ubiquitous 
expression of TG2 is due to constitutive expression in endothelial cells, smooth 
muscle cells, and fibroblasts (Thomazy & Fesus, 1989).  TG2 is localized 
predominantly in the cytoplasm (80%), partly in the plasma membrane and ECM 
(10~20%), and sparsely in the nucleus (5%) (Bruce & Peters, 1983).  Since there 
is no leader peptide or transmembrane domain in TG2 (Gentile et al., 1991; Liu 
et al., 2002), the mechanism by which TG2 is secreted from the intracellular 
compartment onto the cell surface and into the ECM remains unclear. 
However, the Belkin’s laboratory proposed that TG2 is secreted via non-
classical, ER/Golgi-independent pathway, which involves endosomal trafficking 
(Evgeny A Zemskov, Mikhailenko, Hsia, Zaritskaya, & Belkin, 2011).  This 
endosome-mediated TG2 externalization is processed through phosphoinositide-
dependent recruitment of cytoplasmic TG2 to the perinuclear recycling 
endosome, its delivery inside these vesicles, their anterograde trafficking, and 
their fusion with the plasma membrane, which in turn releases TG2 onto the cell 
surface.  In addition, Belkin and co-workers reported that this non-classical 
externalization of TG2 is regulated by nitric oxide via protein trafficking inhibition 
(Santhanam, Berkowitz, & Belkin, 2011). 
TG2 is structurally and functionally a multi-functional protein with both 
intracellular and extracellular functions (Mehta et al., 2010).  TG2 is structured 
with four distinct domains:  an N-terminal β-sandwich domain, a catalytic domain, 
and two C-terminal β-barrel domains (Mehta et al., 2010) (Figure 6).  The N-
terminal β-sandwich domain contains high affinity binding site for fibronectin, 
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which promotes attachment of cells to extracellular matrix (ECM) and enhance 
cell growth, survival, and motility.  The catalytic core domain includes a catalytic 
triad (Cys277, His335, and Asp358) and a Ca2+ binding site.  Exposure to Ca2+ 
induces crosslinking of various cellular proteins and leads to apoptosis or 
inflammation.  The C-terminus β-barrel 1 and 2 domains are arranged in 
antiparallel β-barrels and contain a GTP/GDP binding site.  The C-terminal 
domains are important in regulating transamidation activity and GTPase activity 
which are related to the TG2 signaling pathways involved in cell survival, cell 
growth, and invasion.  The C-terminus β-barrel 2 domain can interact with and 
activate phospholipase C and contribute to inflammation in GTP-bound state 
(Griffin et al., 2002; Mehta et al., 2010). 
 
 
 
Figure 6.  Schematic representation of the structural and functional domains of TG2.  
TG2 contains four distinct domains, and each domain has unique function.  The N-
terminal β-sandwich domain contains fibronectin-binding site and is responsible for cell 
adhesion to the ECM.  The α/β catalytic core contains catalytic triad and Ca2+-binding 
sites and is responsible for crosslinking reaction, contributing to cell death.  The C-
terminal β-barrels contain GTP/GDP binding sites that play an important role in cell 
survival signaling pathways.  Phospholipase C also can bind to β-barrel 2, involving in 
inflammation.  This figure is modified after “Transglutaminase 2: A multi-tasking protein 
in the complex circuitry of inflammation and cancer” by K. Mehta, A. Kumar, and H. Kim, 
Biochemical Pharmacology, 80, p. 1921-1929 © 2010 Elsevier Inc. 
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The functions of TG2 depend on its subcellular localization and 
interaction with its regulators (Figure 7).  Calcium (Ca2+) and GTP are the two 
crucial regulators, and the binding of Ca2+ and GTP inversely regulate TG2 
activity through alteration of the TG2 protein conformation (Di Venere et al., 
2000; Pinkas, Strop, Brunger, & Khosla, 2007; E. A. Zemskov, Janiak, Hang, 
Waghray, & Belkin, 2006).  TG2 binding of Ca2+ causes an extended-form 
conformation exposing the active catalytic site and exerting enzymatic activity, 
but inhibits binding and hydrolysis of GTP.  TG2 binding to GTP induces a 
compact conformation and inhibits the TG catalytic activity (Iismaa et al., 2009).  
In the cytoplasm where Ca2+ concentration is low, TG2 transamidating activity is 
inhibited, while the GTPase, the disulfide isomerase, and the protein kinase 
function may be activated (Fesus & Piacentini, 2002; Pinkas et al., 2007).  Influx 
of extracellular Ca2+ by cellular stress or release of Ca2+ from intracellular 
storages, such as endoplasmic reticulum (ER), can activate TG2 catalytic 
activity. 
In contrast, TG2 on the cell surface and in the ECM, where the Ca2+ 
concentration is high, promotes cell-matrix interactions by binding to integrins 
and fibronectin and by modifying extracellular proteins (Griffin et al., 2002).  TG2 
in the nuclear compartment associates with histones and has been implicated in 
phosphorylation of the histones at Ser (10), and histones 1 and 3 in chromatic 
preparations (Kuo, Tatsukawa, & Kojima, 2011). 
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Figure 7.  Corresponding functions of TG2 depending on its localization and 
conformation.  1) Various stimuli up-regulate TG2 expression.  2) Under normal 
conditions, Ca2+ concentration is low and GTP concentration is high, causing TG2 to 
adopt a closed conformation and be catalytically inactive.  TG2 can promote cell 
adhesion, survival, growth and motility.  3) Influx of Ca2+ into the intracellular 
compartment due to stress leads TG2 to open and become enzymatically active.  4) 
Active TG2 crosslinks intracellular proteins and leads to 5) apoptosis.  6) Externalized 
TG2 is catalytically active by binding to Ca2+ and crosslinks and stabilizes ECM proteins, 
promoting cell adhesion and motility.  Figure is modified from “Transglutaminase 2: A 
multi-tasking protein in the complex circuitry of inflammation and cancer” by K. Mehta, A. 
Kumar, and H. Kim, 2010, Biochemical Pharmacology, 80, p. 1921-1929 © 2010 
Elsevier Inc. 
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1.4.2-a.  Catalytic function of TG2 
TG2, in a Ca2+-dependent manner, crosslinks ECM proteins by catalyzing 
the formation of protease-resistant covalent ε-(γ-glutamyl)-lysine isopeptide 
bonds between donor lysine residue of one protein and acceptor glutamine 
residue of another protein (Griffin et al., 2002; Lorand & Graham, 2003; Mchta, 
2005).  This transamidating activity alters ECM deposition and promotes cell 
adhesion, migration, invasion, and ECM stabilization (Mehta, 2009).  Enzymatic 
substrates of TGases, particularly TG2, include nuclear (Rb and histones), 
cytoplasmic (RhoA and eIF5A), cytoskeletal (β-tubuline, tau, troponin, actin, and 
myosin), membrane (C-CAM), and ECM (FN, fibrinogen, vitronectin, collagen, 
laminin, nidogen, osteopontin, ostesonectin, osteocalcin, and LTBP-1) target 
proteins (E. A. Zemskov et al., 2006) (Table 2).  Type I collagen, one of the ECM 
proteins, is abundant in the human body and is known to be a substrate for TG2, 
which causes formation of ε-(γ-glutamyl)-lysine isopeptide bonds between 
molecules (Chau, Collighan, Verderio, Addy, & Griffin, 2005).  TG2-mediated 
type I collagen crosslinking results in increased strength and stability of collagen 
fibers and resistance to proteolytic degradation (Chau et al., 2005; Orban et al., 
2004). 
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Table 2.  Known TG2 substrates 
 
Intracellular proteins 
• Cytosolic proteins Aldolase A 
Glyceraldehyde-3-phosphoate dehydrogenase 
Phosphorylase kinase 
Crystallins 
Glutathione S-transferase 
• Cytoskeletal proteins Actin 
Myosin 
Troponin 
Β-tubulin 
Tau 
Rho A 
• Organelle proteins Histone H2B 
Α-Oxaloglutarate dehydrogenase 
Cytochromes 
Erythrocyte band III 
CD38 
Acetylcholine esterase 
Extracellular proteins 
• Matrix-associated proteins Collagen 
Fibronectin 
Fibrinogen 
Vitronectin 
Osteopontin 
Nidogen 
Laminin 
LTBP-1 
Osteonectin 
Osteocalcin 
• Signaling proteins and 
peptides 
Substance P 
Phospholipase A2 
Midkine 
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1.4.2-b.  Non-catalytic functions of TG2 
TG2 as a GTPase: 
In addition to its Ca2+-dependent enzymatic activity, TG2 functions as a 
GTPase (Mhaouty‐Kodja, 2004; Nakaoka et al., 1994).  Achyuthan et al. have 
found that guanosine 5’-triphosphate (GTP) and guanosine diphosphate (GDP) 
bind to guinea pig liver TGase and inhibit its transamidation activity, which can be 
reversed by Ca2+ (Achyuthan & Greenberg, 1987).  In addition, Lee et al. have 
reported that TGase purified from guinea pig liver hydrolyzes GTP (Lee, 
Birckbichler, & Patterson, 1989).  Following this report, Im et al. reported a 74-kD 
GTP binding protein (G-protein; Gah), which is involved in α1-adrenergic receptor 
(α1-adrenoceptor)-mediated activation of phospholipase C (PLC-δ1) (Im & 
Graham, 1990).  The activated PLC hydrolyzes phosphatidylinositol diphosphate 
(PIP2) to inositol triphosphate (IP3), an inducer of Ca2+ release from intracellular 
organelles, and diacylglycerol (DAG), an activator of protein kinase C, which 
plays a role in various biological processes.  Im et al. have also reported that Gah 
forms a complex with the 50-kD subunit Gbh (Im, Riek, & Graham, 1990), an 
inhibitory regulator of Gah (Baek et al., 1996).  Later, Nakaoka et al. reported that 
Gah was in fact TG2 possessing both TGase activity and G-protein coupled 
receptor (GPCR) signal transduction function (Nakaoka et al., 1994).  
As reported by Im et al., binding of GTP/GDP on Gah (TG2) leads to a 
compact (closed), catalytically inactive conformation of Gah (TG2).  Binding of an 
agonist to the α1-adrenoceptor drives conformational change of GPCR, which in 
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turn activates the Gah (TG2) by releasing GDP and binding GTP.  Once GTP is 
bound, Gah (TG2) dissociates from both the α1-adrenoceptor and Gbh.  The GTP-
bound Gah (TG2) interacts with the effector (PLC), which produces the second 
messenger (DAG) to amplify signals important in biological activities including 
sympathetic nervous system responses, platelet aggregation and secretion, 
vasoconstriction, and mitogenesis.  Once GTP is hydrolyzed to GDP and Pi by 
the GTPase function of Gah (TG2), GDP-bound Gah (TG2) dissociates from the 
effector and re-associates with Gbh, completing an activation/deactivation cycle of 
GTPase (Im et al., 1990). 
TG2 as a serine/threonine kinase: 
Mishura and Murphy have reported that TG2 also has an intrinsic kinase 
activity.  They identified TG2 in the kinase fraction associated with the insulin-like 
growth factor-binding protein-3 (IGFBP-3) in T47D breast cancer cells (S. Mishra 
& Murphy, 2004).  They found that TG2 is able to phosphorylate IGFBP-3 and 
IGFP-5 at multiple serine and threonine residues, and that this kinase activity can 
be inhibited by Ca2+, in a concentration-dependent manner.  The authors also 
identified p53 (Suresh Mishra & Liam J Murphy, 2006), H1, H2A, H2B, H3, H4 
histones (Suresh Mishra, Saleh, Espino, Davie, & Murphy, 2006), and 
retinoblastoma protein (Rb) (Suresh Mishra, Melino, & Murphy, 2007) as other 
substrates of TG2 kinase activity.  TG2-mediated phosphorylated p53 blocks the 
interaction between p53 and Mdm2, and TG2-mediated phosphorylated Rb 
disrupts the Rb/E2F1 complex, which has an important role in the regulation of 
the cell cycle (Suresh Mishra et al., 2007; S. Mishra & L. J. Murphy, 2006).  In 
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addition, they have discovered that TG2 is also phosphorylated by the protein 
kinase A (PKA), which in turn abolishes the protein’s transamidating activity and 
enhances its kinase function (Suresh Mishra et al., 2007).  These findings 
suggested that activation of PKA leads to phosphorylation of TG2, which 
phosphorylates Rb. 
TG2 interaction with fibronectin:  
TG2 forms ternary complex with fibronectin (FN) and integrin on the cell 
surface where all three proteins can interact with each other, facilitating cell 
adhesion and migration (Turner & Lorand, 1989).  TG2 contains a FN binding 
domain on the β-sandwich domain located at the TG2 N-terminus spanning 
amino acids 88 to 106 (Hang, Zemskov, Lorand, & Belkin, 2005).  A 42 kDa sub-
domain of FN consisting of I6 II1,2 I7-9 modules binds to the FN binding domain on 
TG2 with a high affinity, facilitating cell adhesion to the ECM through β-integrins 
(Akimov & Belkin, 2001; Radek, Jeong, Murthy, Ingham, & Lorand, 1993).  
Formation of FN-TG2-β-integrin ternary complex activates cell survival and 
triggers motility-associated signaling pathways including the focal adhesion 
kinase (FAK), Raf-1, and GTP-binding protein, Rho (Hang et al., 2005; Janiak, 
Zemskov, & Belkin, 2006).  These interactions do not require Ca2+ and are 
independent of the transamidation and GTPase activity of TG2.  Since most 
integrin ligands in the ECM are substrates for TG2, the extracellular TG2 is 
involved in the assembly, remodeling, and stabilization of ECM in various tissues 
(Aeschlimann & Thomazy, 2000). 
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TG2 as a protein disulphide isomerase: 
Hasegawa et al. have described a novel function of TG2 as a protein 
disulphide isomerase (PDI) (Hasegawa et al., 2003).  PDIs are members of the 
thioredoxin superfamily, which resides in the lumen of the endoplasmic reticulum 
(ER), supporting conformational changes of proteins by forming disulphide 
bridges within polypeptides (Ferrari & Soling, 1999; Freedman, Hirst, & Tuite, 
1994; Noiva & Lennarz, 1992).  The authors have shown that TG2 converts 
reduced/denatured inactive RNase A molecule to the native active enzyme, and 
this PDI function could be inhibited by bacitracin, a typical PDI inhibitor, and 
reduced BSA, but not by Ca2+ or GTP (Hasegawa et al., 2003). 
1.4.3.  TG2 and diseases 
 Up-regulation of TG2 has been evidenced in various human pathological 
conditions (Figure 8) such as degenerative neurological diseases (Junn, 
Ronchetti, Quezado, Kim, & Mouradian, 2003), autoimmune diseases (Sollid, 
Molberg, McAdam, & Lundin, 1997), fibrosis and atherosclerosis (Grenard et al., 
2001; T. S. Johnson et al., 1999; S.-Y. Kim, Jeitner, & Steinert, 2002), chronic 
inflammatory diseases (Elisabetta AM Verderio, Johnson, & Griffin, 2005), 
neoplastic disease (Barnes, Bungay, Elliott, Walton, & Griffin, 1985), and 
cancers.  Especially, TG2 expression is increased in ovarian cancer (L Cao et al., 
2012; Satpathy et al., 2007), breast carcinoma (Herman, Mangala, & Mehta, 
2006), malignant melanoma (Fok, Ekmekcioglu, & Mehta, 2006), lung carcinoma 
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(Park et al., 2010), and pancreatic cancer (Verma et al., 2006)  as shown in 
several studies. 
 TG2 expression in cancer is directly related to cancer progression, 
chemoresistance (Kotsakis & Griffin, 2007), pro- or anti-apoptotic effects (Fesus 
& Szondy, 2005), and invasiveness (Mehta et al., 2010).  Because of these 
observations, TG2 expression is usually associated with poor survival.  TG2 
expression can be induced by various cytokines and growth factors, such as 
TGF-β (Quan, Choi, Lee, & Lee, 2005) and IL-6 (Suto, Ikura, & Sasaki, 1993).  
TG2 is up-regulated in ovarian cancer (OC) cells compared to normal ovarian 
epithelial cells by TGF-β (L. Cao et al., 2012; Matei et al., 2002), and induces 
intraperitoneal dissemination by enhancing cancer cell adhesion to the ECM and 
interaction with integrins (Satpathy et al., 2007).  Down-regulation of TG2 in OC 
cells decreased adhesion and migration in vitro and intraperitoneal dissemination 
in vivo. 
 In the context of apoptosis, TG2 acts either as an inducer or as an 
inhibitor via cellular specific mechanisms.  Under physiological conditions, 
intracellular TG2 is enzymatically inactive due to low Ca2+ concentrations and 
high GTP concentrations.  When Ca2+ influx occurs during the late phases of 
apoptosis, TG2 crosslinks cytosolic proteins and finalizes the cell death process 
(Lorand & Graham, 2003).  On the other hand, TG2 plays an anti-apoptotic role 
in malignant cells by promoting cell survival (e.g. NF-κB) and activating anti-
apoptotic (e.g. FAK, PI3K/Akt) signaling pathways, which will be described in 
detail in next section. 
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 Overall, these studies suggest TG2 involvement in the process of 
chemotherapy resistance and support developing TG2 inhibitors as anticancer 
therapy (Yuan et al., 2005).  
 
 
 
Figure 8.  TG2 involvement in human diseases.  Conformational changes of TG2 
induced by Ca2+ concentrations regulate the TG2 functions that are associated with 
different pathological and physiological conditions. 
 
 
 
 
1.4.3-a.  TG2 in Pancreatic Cancer 
 TG2 is a highly expressed protein in pancreatic tumors (Cheung et al., 
2008; Iacobuzio-Donahue et al., 2003; Verma et al., 2006).  Elevated TG2 
expression in PDA cells was linked to development of drug resistance, metastatic 
phenotype, and poor patient prognosis (Iacobuzio-Donahue et al., 2003; Verma, 
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Guha, Diagaradjane, et al., 2008).  Mehta and colleagues reported elevated TG2 
expression in the majority of drug resistant and metastatic PDA tumors and cell 
lines (Verma et al., 2006).  TG2 expression level was high in 42 out of 75 (56%) 
PDA tumor samples compared to normal pancreatic ducts and in all of 12 PDA 
cell lines analyzed.  They reported a trend of increasing TG2 expression with 
increasing tumor stage (T1, 3 out of 5 (60%); T2, 32 out of 44 (73%); T3, 13 out 
of 16 (81%)). 
In these studies, the elevated TG2 expression in PDA was associated with 
constitutive activation of the nuclear factor κB (NF-κB) and of the focal adhesion 
kinase (FAK)/phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway leading 
to chemo-resistance and invasive phenotypes (Mann et al., 2006; Verma, Guha, 
Diagaradjane, et al., 2008; Verma, Guha, Wang, et al., 2008).  In addition, TG2 
expression was promoted by the activation of protein kinase Cδ (PKCδ), resulting 
in inhibition of autophagy in PDA cells (Akar et al., 2007). 
NF-κB is a transcription factor that contains a highly conserved DNA-
binding domain called the Rel homology domain (Ghosh et al., 1998), and in 
cancer, it plays an important role in regulation of cell growth, metastasis, and 
apoptosis (D.-S. Kim et al., 2006; Mann et al., 2006; Mehta, Fok, Miller, Koul, & 
Sahin, 2004; Verma et al., 2006).  Under normal conditions, NF-κB is present in 
an inactive form in cells by interacting with IκBα, a cytosolic protein that functions 
to inhibit NF-κB through non-covalent association with the DNA-binding domain 
of NF-κB.  Under various stimuli including oxidative stress, cytokines, growth 
factors, or in the presence of bacterial or viral antigens, NF-κB is activated by 
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dissociation from IκBα and translocates to the nucleus leading to increased 
expression of target genes.  Such genes are involved in cell growth, adhesion, 
migration, and apoptosis inhibition (Karin et al., 2002; Nakanishi & Toi, 2005).  
Generally, cellular response to various stimuli is well controlled by transient 
activation of NF-κB.  However, in PDA, NF-κB is constitutively activated due to 
unregulated binding of IκBα to the DNA-binding domain of NF-κB (Bours, 
Dejardin, Goujon-Letawe, Merville, & Castronovo, 1994; Wang et al., 1999).  
Mann et al. have shown that TG2 forms a complex with IκBα and directly 
crosslinks IκBα (Mann et al., 2006).  The crosslinked IκBα dissociates from the 
Rel homology domain of NF-κB and is processed for proteasomal degradation, 
resulting in nuclear localization and constitutive activation of NF-κB.  
Overexpression of TG2 or direct activation of TG2 by treatment with Ca2+ 
ionophore resulted in activation of NF-κB in PDA cells.  In addition, down-
regulation of TG2 expression level by transfecting TG2-specific small interfering 
RNA (siRNA) and inhibition of TG2 enzymatic activity by using TG2-specific 
inhibitors, monodansylcadaverine and 5-(Biotinamido)pentylamine (BPA), in PDA 
cells expressing abundant TG2 resulted in reduced activation of NF-κB by 
increased formation of IκBα and NF-κB complex.  These observations support 
that elevated TG2 expression is a key player in the constitutive activation of NF-
κB in PDA.  
FAK is a cytosolic protein tyrosine kinase that is involved in cell adhesion, 
migration, and survival via its downstream phosphatidylinositol 3-kinase 
(PI3K)/AKT signaling pathway (Verma et al., 2006).  In the presence of stimuli, 
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such as growth factors and integrin engagement, FAK is phosphorylated and 
activated, which leads to activation of PI3K/AKT signaling pathway (J. Zhao & 
Guan, 2009).  The activation of FAK/PI3K/AKT signaling pathway is negatively 
regulated by the tumor suppressor, PTEN (phosphatase and tensin homologue) 
(Maehama & Dixon, 1998; Tamura et al., 1998).  PTEN directly interacts with 
FAK and inactivates it by dephosphorylation, and also dephosphorylates PIP3 
(phosphatidylinositol (3,4,5)-trisphosphate), resulting in the inhibition of the 
FAK/PI3K/AKT signaling pathway. 
Verma et al. have shown that elevated expression of TG2 in PDA 
contributed to drug resistant and metastasis via activation of FAK (Verma et al., 
2006).  Resistance to gemcitabine treatment and invasiveness as measured 
through matrigel-transwell assay were correlated with higher expression level of 
either TG2 or of its mutant, C277S, in PDA cells.  In addition, overexpression of 
TG2 in low TG2-expressing PDA cells increased FAK activation leading to AKT 
activation, while down regulation of TG2 with siRNA in PDA cells diminished FAK 
activation, suggesting that the elevated TG2 expression induces constitutive 
activation of FAK and may contribute to the drug resistance and invasion in PDA, 
independent of its enzymatic activity. 
In addition, they showed that TG2 directly interacts with PTEN, inhibits its 
phosphorylation at Ser380, and promotes ubiquitination of PTEN, leading to 
proteasomal degradation in PDA cells (Verma, Guha, Wang, et al., 2008).  An 
inverse correlation between TG2 expression levels and PTEN was demonstrated 
in high TG2-expressing PDA cell lines.  Overexpression of TG2 in low TG2-
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expressing PDA cell lines decreased PTEN expression.  On the other hand, 
down-regulation of TG2 in high TG2-expresssing cell lines by transfecting TG2-
specific shRNA or siRNA increased total PTEN expression and phosphorylation.  
Overexpression of mutated, catalytically inactive TG2 (C277S) in low TG2-
expressing PDA cells inhibited PTEN expression and phosphorylation, 
suggesting that TG2-mediated regulation of PTEN expression is independent of 
its enzymatic activity.  Moreover, treatment of TG2 overexpressing PDA cells 
with cycloheximide, a protein biosynthesis inhibitor, in the presence of MG132, a 
proteasome inhibitor, resulted in the accumulation of ubiquitinated PTEN without 
alteration in PTEN expression, suggesting that TG2 inhibits PTEN 
phosphorylation and promotes its ubiquitination, which results in proteasomal 
degradation.  In addition, 51 specimens of stage II human PDA on a tissue 
microarray (TMA) was analyzed and reported that 11 out of 32 (34%) TG2-
expressing specimens showed weak PTEN expression, while 13 out of 19 (68%) 
TG2-negative specimens expressed strong PTEN (Verma, Guha, Wang, et al., 
2008). 
Overall, these results supported that overexpression of TG2 in PDA 
activates FAK/PI3K/AKT cell survival signaling pathway by inhibiting expression 
and phosphorylation of the tumor suppressor protein PTEN and promoting its 
proteasomal degradation. 
Autophagy is a process involved in the degradation of protein aggregates 
and dysfunctional organelles through the autophagosome-lysosome system 
(Rossin et al., 2014).  Cellular waste is captured in autophagosome, and the 
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autophagosomes merge with lysosomes where digestion event of organelles 
occurs (Mizushima, 2007).   
Akar et al. have shown that PKCδ, an enzyme involved in cell growth, 
differentiation, and apoptosis, promotes the expression of TG2, which in turn 
inhibits autophagy in PDA cells (Akar et al., 2007).  Inhibition of PKCδ by a 
PKCδ-specific inhibitor, rottlerin, or by siRNA down regulated the expression of 
TG2 in PDA cells and resulted in inhibition of cell growth.  Additionally, treatment 
with rottlerin or TG2 knockdown (siRNA) in PDA cells led to accumulation of 
microtubule-associated protein 1 light chain 3 (LC3)-II protein; a marker of 
autophagy, and formation of autophagosomes in cytoplasm, suggesting that TG2 
regulates autophagy.  The importance of Beclin-1, an autophagy stimulator, was 
shown by knocking down Beclin-1, which inhibited rottlerin- and TG2 siRNA-
induced autophagy in PDA cells.  These findings support that elevated TG2 
expression in PDA cells inhibits autophagy leading to development of drug 
resistance.  
 PDA generally displays intrinsic resistance to chemo- and radio-therapy, 
but the molecular mechanisms of resistance are not well understood (Willett et 
al., 2005).  Based on the observations that TG2 expression activates 
FAK/PI3K/AKT signaling pathway and NF-κB (Mann et al., 2006; Verma, Guha, 
Wang, et al., 2008; Verma et al., 2006), Verma et al. assessed the effect of TG2 
inhibition on PDA cell response to chemotherapeutic drug (Verma, Guha, 
Diagaradjane, et al., 2008).  They delivered TG2-specific siRNA-DOPC (1,2-
dioleoyl-sn-glycero-3-phosphatidylcholine) liposome to orthotopic xenograft mice 
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via intravenous injection, with or without administration of gemcitabine via 
intraperitoneal injection.  The mice injected with the combination of TG2 siRNA-
DOPC and gemcitabine showed significantly decreased tumor growth and 
inhibited metastasis.  In addition, TG2 inhibition reduced cell proliferation, 
angiogenesis, and phosphorylation of AKT.  Overall, these results support that 
the inhibition of TG2 sensitizes PDA tumors to gemcitabine. 
 
1.5.  Research objectives 
Pancreatic ductal adenocarcinoma (PDA) is a very aggressive and lethal 
disease, which metastasizes rapidly and is resistant to chemotherapeutics.  A 
unique hallmark of the PDA is the presence of dense desmoplastic stroma (DS), 
which is composed of myofibroblasts, pancreatic stellate cells, collagen, and 
other extracellular matrix proteins (ECM).  Tissue transglutaminase (TG2) is 
highly expressed in PDA cells and has been reported to be involved in tumor 
progression and chemotherapy resistance.  However, the role of TG2 in PDA 
stroma is largely unknown.  The goal of this study was to understand how up-
regulated TG2 in PDA cells contributes to tumor progression and stroma 
alteration. 
 Knowing that TG2 is secreted into the ECM, where it crosslinks matrix 
proteins, I hypothesized that TG2 secreted from PDA cells promotes PDA 
tumor progression by modulating the tumor microenvironment (TME) 
(Figure 9).  Specifically, I proposed that TG2 1) promotes tumor formation and 
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progression by 2) modulating composition of PDA stroma and 3) altering 
cellular signaling in PDA cells, which result in 4) decreased response of 
tumors to chemotherapy.  TG2 in the TME provides a stable and protective 
tumor milieu for PDA progression through several mechanisms, which were 
investigated in the following specific aims. 
Aim 1:  Test the hypothesis that TG2 regulates tumor progression.  As 
abundant TG2 was detected in PDA specimens and in PDA cells, I determined 
whether TG2 promotes tumor progression.  An orthotopic xenograft mouse 
model was generated by implanting TG2 expressing (control) or knockdown 
(shTG2) PDA cells directly into the tail of pancreas of female nude mice.  Tumor 
formation and growth were compared between control and shTG2 xenografts. 
Aim 2:  Test the hypothesis that TG2 alters stroma composition.  As the 
most abundant components of the stroma are stromal cells and collagen type I, I 
assessed whether TG2 can activate and promote proliferation of fibroblasts, 
increase deposition of collagen, and induce crosslinking function on collagen, in 
vitro and in vivo.  
Aim 3:  Test the hypothesis that TG2-mediated modulated stroma alters 
cellular signaling in PDA cells.  As the PDA stroma progresses through 
hyperplastic desmoplasia, its physiological properties become dense and stiff.  
YAP and TAZ transcription factors regulate cancer cell proliferatioin and survival, 
and are regulated by mechanotransduction among other mechanisms.  I tested 
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whether YAP and TAZ in the PDA cells are activated by the surrounding TG2-
mediated stiff environment, thereby, inducing proliferation of PDA cells. 
Aim 4:  Test the hypothesis that TG2-mediated modified stroma alters the 
response of tumors to chemotherapy.  The PDA stroma is heterogenous and 
highly desmoplasic.  I determined whether the tumors derived from TG2 
expressing PDA cells are protected from the effects of gemcitabine, a common 
chemotherapeutic agent for PDA. 
By testing the hypothesis, we observed involvement of TG2 in pancreatic 
tumor progression and chemoresistance through stroma modification, supporting 
that TG2 is a potential therapeutic target within the PDA supportive stroma.  
From a clinical standpoint, depletion of TG2 in the PDA stroma may improve the 
response to chemotherapy in PDA patients by providing increased drug 
penetrance into the tumor milieu and by inhibiting tumor growth and progression. 
 
 
 
Figure 9.  Schematic diagram of hypothesis.  TG2 secreted from PDA cells promotes 
PDA progression by modulating the tumor microenvironment. 
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CHAPTER 2.  MATERIALS AND METHODS 
2.1.  Antibodies 
Western blot (WB): Tissue transglutaminase 2 monoclonal Ab 
(NeoMarkers, Fremont, CA; #CUB7402), GAPDH monoclonal Ab (Meridian Life 
Science, Inc., Memphis, TN; #C01448M), YAP1 monoclonal Ab (Abnova, Walnut, 
CA; #H00010413-M01), phospho-YAP (Ser127) monoclonal Ab (Cell Signaling 
Technology, Danvers, MA; #13008S), YAP/TAZ monoclonal Ab (Cell Signaling 
Technology, #8418), donkey anti-rabbit IgG-HRP (GE Healthcare Life Sciences, 
Pittsburgh, PA; #NA9340V), and goat anti-mouse IgG-HRP (Santa Cruz 
Biotechnology, Dallas, TX; #sc-2005). 
Immunohistochemistry (IHC): Tissue transglutaminase 2 polyclonal Ab 
(NeoMarkers, #RB-060-P1ABX), Isopeptide (Abcam, Cambridge, MA; #ab424), 
α-SMA (IHC World, Woodstock, MD; #IW-MA1106), Universal LSABTM2 
Kit/HRP, Rabbit/Mouse (Dako North America, Inc., Carpinteria, CA; #K0675), 
and Liquid DAB+ Substrate Chromogen System (Dako North America, Inc.; 
#3468). 
Immunofluorescence (IF): Tissue transglutaminase 2 monoclonal Ab 
(same as WB), α-SMA monoclonal Ab (Sigma-Aldrich, St Louis, MO; #F-3777), 
Collagen I polyclonal Ab (Abcam, #ab34710), YAP/TAZ (same as WB), CyTM5-
Conjugated ZyMaxTM goat anti-mouse IgG (H+L) (Invitrogen Corporation, 
Camarillo, CA; #81-6516), Alexa Fluor® 488 goat anti-rabbit IgG (H+L) (Life 
Technologies, Carlsbad, CA; #A11008), Streptavidin-Alexa Fluor® 647 (Life 
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Technologies, #S32357), and VECTASHIELD Mounting Medium with DAPI 
(Vector Laboratories, Burlingame, CA; #H-1200). 
 
2.2.  Cell lines and cell cultures 
Cell lines:  AsPC1, BxPC3, and Paca2 cells were obtained from the 
American Type Culture Collection (Rockville, MD), and human pancreatic normal 
epithelial (HPNE) and Panc1 cells were a gift from Prof. Murray Korc of Indiana 
University Simon Cancer Center (IUSCC) (Shannon HE, 2014).  The PDA cells 
were tested and found to be mycoplasma free by the IUSCC In Vivo 
Therapeutics Core.  The human pancreatic cancer associated fibroblasts 
(hpFibroblasts) were isolated from a human pancreatic tumor and immortalized 
by transduction of telomerase (hTERT); details will follow in the next section.  
The normal human dermal fibroblasts (NHF544) were provided by Dr. Dan 
Spandau from IU School of Medicine, and green fluorescence protein expressing 
human neonatal dermal fibroblasts (GFP-HNDFs) were purchased from 
Angioproteomie (Boston, MA; #cAP-0008GFP).  Human pancreatic stellate cells 
(hPSCs) were from ScienCell Research Laboratories (Carlsbad, CA; #3830), and 
the human mesothelial cell line, LP9, was from the NIA Aging Cell Repository 
(Camden, NJ).  
Cell Culture:  AsPC1 and BxPC3 cells were cultured in Roswell Park 
Memorial Institute (RPMI) 1640 medium (Cellgro, Manassas, VA; #10-040-CV) 
supplemented with 10% fetal bovine serum (FBS) (Cellgro; #35-011-CV) and 1% 
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antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin, HyClone Laboratories, 
Inc., Logan, Utah; #SV30010).  Panc1, Paca2, HPNE, hpFibrobasts, NHF544, 
GFP-HNDFs, hPSCs, and LP9 cells were grown in Dulbecco's modified Eagle's 
medium (DMEM, Cellgro; #10-013-CV) supplemented with 10% FBS, and 1% 
antibiotics.  Cells were grown at 37°C under 5% CO2.  Serum-free conditioned 
media (CM) was collected after 24 hour incubation of 5x105 PDA cells in RPMI 
media by centrifugation of collected media at 1,200 rpm for 5 min prior to transfer 
of CM to sterile tubes. 
 
2.3.  Cell transduction and transfection 
TG2 was stably knocked down in AsPC1 and Panc1 cells by transducing 
cells with MISSION® shRNA Lentiviral Transduction Particles (Sigma; #SHCLNV-
NM-004613: TRCN0000000239, 0000000243, 0000272816, 0000272817, and 
0000284849), containing short hairpin RNAs (shRNA) targeting TG2 (shTG2) in 
the presence of polybrene (8µg/mL).  As a control (shCtrl), cells were transduced 
with MISSION® pLKO.1-puro Empty Vector control Transfection Particles (Sigma; 
#SHC001V).  Both shCtrl and shTG2 particles were transduced at a 2.5 
multiplicity of infection.  Pooled stable clones were collected after selection with 
puromycin (1 µg/ml), and TG2 knockdown was verified by western blotting. 
Transient transfection of short interfering RNA (siRNA) was performed 
with sequences targeting YAP and TAZ (Santa Cruz Biotechnology, Inc.; #sc-
38637 and #sc-38568, respectively) using Lipofectamine® 3000 (Life 
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technologies, Carlsbad, CA; #L3000008).  Dharmacon™ siGENOME™ Control 
Pool (Dharmacon, Lafayette, CO; #D-001206-13-05) was used as control. 
 
2.4.  Co-culture 
Co-culture experiments utilized 1x104 cells of GFP-HNDFs mixed with 
5x103 PDA cells in 96 wells.  GFP-HNDF proliferation was measured daily for 14 
days by assessing fluorescence intensity (RFUs) using the SpectraMax Gemini 
XS microplate fluorometer (Molecular Devices, Sunnyvale, CA) at 485 nm 
excitation and 538 nm emission. During 14 days of co-culture, with the culture 
media was replenished every other day.  
To determine the effect of PDA cells on activation of fibroblasts and 
collagen deposition, NHF544 cells (2.5x104) were cultured in a mixture with PDA 
cells (2.5x104) transduced with shRNAs, plated on an 8-well Millicell® EZ SLIDE 
(Millipore, Billerica, MA; #PEZGS0816).  After 24 hours of co-culture, activation 
of fibroblasts and collagen deposition was analyzed by IF using α-SMA and 
collagen 1 antibodies, respectively. 
To study the proliferation of PDA cells in co-culture with hPSCs, 2x105 
hPSCs were seeded in 12-well plates.  24 hours later, 6x104 (Panc1) or 9x104 
(AsPC1) cells were added on top of the hPSCs feeder layer and were allowed to 
proliferate for up to 10 days.  Proliferation of PDA cells was assayed by crystal 
violet staining as described in next section. 
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2.5.  Proliferation assays 
Several cell proliferation assays were used:  cell counting kit (CCK)-8 
assay (Dojindo Molecular Technologies, Inc., Rockville, MD; #CK04), 
bromodeoxyuridine (BrdU) cell proliferation ELISA (Abcam; #ab126556), and 
crystal violet staining. 
The proliferation of NHF544 and hpFibroblasts on native or crosslinked 
collagen used CCK-8, according to the manufacturer’s instructions.  This method 
measures cell proliferation by determining the amount of yellow-colored 
formazan dye generated from tetrazolium salt, WST-8, reduced by 
dehydrogenase activities in live cells.  Absorbance at 450 nm was measured 
using EL800 microplate reader (BioTek Instruments, Inc., Winooski, VT). 
The BrdU assay was used to measure proliferation of PDA cells, following 
the manufacturer’s protocol.  This assay measures the replicating, live cells by 
detecting amount of incorporated BrdU in the DNA during S phase of the cell 
cycle.  Incorporated BrdU in the cells was measured at an absorbance of 370 nm  
by SPECTRAmax® Plus 384 microplate spectrophotometer (Molecular Devices). 
Crystal violet staining was utilized to stain the PDA cells grown on the 
hPSCs feeder layer.  Cells were fixed and stained for 20 min at room 
temperature with Fixing/Staining solution, which contains 0.05% crystal violet 
(w/v), 1% formaldehyde, 1X PBS, and 1% methanol.  The dye was solubilized in 
methanol, and absorbance at 540 nm was measured on the SPECTRAmax® 
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Plus 384 spectrophotometer (Molecular Devices).  Experiments were performed 
in 4 replicates and were repeated 2-3 times. 
 
2.6.  Western blot analysis 
Cells were lysed in Radio-Immunoprecipitation Assay (RIPA) buffer 
containing Halt™ protease inhibitor cocktail (Thermo Scientific).  Equal amounts 
of proteins were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), and transferred to Immuno-Blot polyvinylidene 
difluoride (PVDF) membranes (Bio-Rad Laboratories, Inc.).  After blocking, 
membranes were blotted with primary antibodies followed by HRP-conjugated 
secondary antibodies.  The protein-antibody complexes were visualized by 
enhanced chemiluminescence solution (Thermo Scientific), and images were 
captured by ImageQuant LAS 4000 mini imager with a Chemilux CCD camera 
(GE Healthcare, Uppsala, Sweden).  Densitometry assessment was performed 
by using ImageJ software.  All analyses were repeated at least 3 times. 
 
2.7.  Orthotopic pancreatic xenografts 
To study tumor growth, 1.5x105 AsPC1 and 2 x105 Panc1 cells, stably 
transfected with shRNA targeting TG2 or scrambled (control) as mentioned in 
2.3. section, suspended in 50 µl of medium were injected directly into the tail of 
pancreas of 7-8 weeks old female nude mice (nu/nu Balbc) from Harlan 
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(Indianapolis, IN) using a 27.5 gauge needle under isoflurane anesthesia.  The 
mice were euthanized after three (for Panc1 cells) or 4 weeks (for AsPC1 cells) 
after cell injection.  Twelve mice per group were injected with AsPC1±shTG2 
cells and 7 mice per group were injected with Panc1±shTG2 cells.  Pancreatic 
tumors were weighted and measured three-dimensionally and tumor volume was 
calculated as 4/3*π*(L/2)*(W/2)*(H/2); where L is length, W is width, and H is 
height.  Metastatic implants were counted.  
To study the sensitivity to gemcitabine (Gem) in tumors, the orthotopic 
xenograft mice with AsPC1±shTG2 cells were prepared as described above and 
dosed with Gem either one time or twice a week for 4 weeks. 
One dose of Gem:  Four weeks after cell injection (shCtrl; n=5, shTG2; 
n=6), Gem at a concentration of 50mg/kg was administered to the mice via 
intravenous injection, and the mice were euthanized after 2 minutes of Gem 
administration due to rapid uptake and excretion of Gem in pancreas (Shipley et 
al., 1992).  Tumors and plasma were collected for Gem concentration 
measurement. 
Long-term dose of Gem:  Gem at a concentration of 50mg/kg or PBS 
(control) were administered to the orthotopic xenograft bearing mice (n=7 per 
group), twice a week for 4 weeks via intraperitoneal injection.  At 4-week, the 
mice were euthanized, and tumor weight, volume, and number of metastases 
were measured as described above.  
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Animal experiments were approved by the IU Animal Care and Use 
Committee, being in compliance with federal regulations.   
 
2.8.  Immunohistochemistry (IHC) 
Paraffin-embedded de-identified PDA specimens from the IUSCC Tissue 
Bank were immunostained by using antibodies against TG2 (Neomarkers, 1:200 
dilution) and isopeptide (Abcam, Cambridge, MA, 1:100 dilution), after sodium 
citrate antigen retrieval.  Paraffin-embedded pancreatic xenografts were stained 
similarly, using a TG2 polyclonal antibody (NeoMarkers, 1:50 dilution) and ready 
to use α-SMA monoclonal antibody (IHC World) for myofibroblasts.  Secondary 
labeling was based on the Avidin/Biotin system (Dako North America, Inc.).  
Slides were stained with 3-3’ diaminobenzidine (DAB) and counterstained with 
hematoxyllin.  Negative controls were run in parallel, with isotype IgG control.  H 
score was calculated as percentage of stained cells multiplied by intensity of 
staining (graded from 0 to 3+).  All slides were reviewed by a board-certified 
pathologist [Robert Emerson, IUSM].  In total, we stained 75 specimens, of which 
52 tumors were parts of a tissue microarray (TMA), 20 were identified as tumors 
associated with desmoplasia, and 3 were normal pancreas.  The IU Institutional 
Review Board approved the use of de-identified human tissue specimens. 
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2.9.  Immunofluorescence (IF) 
Antibodies for TG2 (Neomarkers), α-SMA (Sigma), collagen 1 (Abcam), 
and YAP/TAZ (Cell Signaling) were used at a 1:100 dilution.  PDA cells were 
cultured on collagen coated (StemCell Technologies, Inc., Vancouver, BC), 
fibronectin coated (BD Biosciences, Bedford, MA), or uncoated slides (Millicell® 
EZ SLIDE, Millipore).  After fixation in 4% paraformaldehyde, cells were 
permeabilized using 0.1% Triton X-100 in PBS for 5 min and blocked for 1 hour 
with 3% goat serum in PBS-T (0.1% Tween 20).  Subsequently, cells were 
incubated overnight at 4°C with antibodies for TG2 (Neomarkers), α-SMA 
(Sigma), collagen 1 (Abcam), and YAP/TAZ (Cell Signaling) at a 1:100 dilution, 
followed by 1 hour incubation with CyTM5-conjugated anti-mouse secondary 
antibody (Invitrogen Corporation) and Alexa Fluor® 488 goat anti-rabbit IgG (Life 
Technologies).  To detect matrix-bound TG2, cells were not permeabilized prior 
to incubation with the TG2 antibody (1:100 dilution), as previously described 
(Faye et al., 2010).  Isotype-specific IgG was a negative control.  Nuclei were 
visualized by 4’,6-diamidino-2-phenylindole (DAPI) staining (VECTASHIELD; 
Vector Laboratories).  Analysis used a Zeiss LSM 510 META confocal 
multiphoton microscope system (Carl Zeiss, Inc., Thornwood, NY, USA) under 
UV excitation at 635 nm for Cy5, 488 nm for Alexa Fluor® 488, and 405 nm for 
DAPI.  
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2.10.  Reporter assay 
To measure YAP/TAZ transcriptional activity, PDA cells were transfected 
with pGal4-TEAD4, pGal4-Luciferase, and pTK-Renilla at a ratio of 1:10:1 using 
DreamFect™ Gold (Oz Biosciences, Inc., San Diego, CA; #DG81000).  Plasmids 
were a gift from Dr. Clark Wells (IUSCC) (Adler et al., 2013).  The Dual-
Luciferase® Assay System kit (Promega, Madison, WI) determined TEAD4 
reporter activity after 48 hours of transfection.  To control for transfection 
efficiency, the luciferase activity was normalized to renilla.  Five replicates per 
group were assessed.  Data are presented as means ± standard error (SE) of 
replicates. 
 
2.11. Reverse transcription PCR (RT-PCR) and quantitative real-time PCR 
(qRT-PCR) 
Total RNA was extracted using RNA STAT-60 Reagent (Tel-Test Inc., 
Friendswood, TX) and reverse-transcribed using iScript cDNA synthesis kit (Bio-
Rad Laboratories, Inc.).  The reverse transcriptase product (1 µl) and primers 
were heated at 94°C for 90-s followed by 24 rounds of amplification for GAPDH 
and 29 cycles for TG2 (30-s denaturing at 94°C, 30-s annealing at 57°C, and 30-
s extension at 72°C) followed by a 10 min final extension at 72°C on a T100™ 
Thermal Cycler (Bio-Rad Laboratories, Inc.).  The RT-PCR product was 
visualized on an ImageQuant LAS 4000 mini imager (GE Healthcare) after 
fractionation on a 1% agarose gel.  For qRT-PCR, the iTaq Universal SYBR 
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Green Supermix (Bio-Rad Laboratories, Inc.) on an ABI Prism 7900 platform 
(Applied Biosystems, Waltham, MA) was used.  Primers used for RT-PCR and 
qRT-PCR are listed in Table 3. 
 
Table 3.  Primers for RT-PCR and qRT-PCR 
 
RT-PCR 
TG2 
Forward ACC CGC GTC GTG ACC AAC TAC AAC  
Reverse GGT GAT ATC CTC CCG CTC GTC TCG 
GAPDH 
Forward GAT TCC ACC CAT GGC AAA TTC C 
Reverse CAC GTT GGC AGT GGG GAC 
      
qRT-PCR 
CTGF 
Forward AGG AGT GGG TGT GTG ACG A  
Reverse CCA GGC AGT TGG CTC TAA TC 
GAPDH 
Forward AGC CAC ATC GCT CAG ACA C 
Reverse GCC CAA TAC GAC CAA ATC C 
 
 
 
 
Relative target gene expression was calculated using Ct method, 2-ΔCt=2-
[Ct(CTGF)-Ct(GAPDH)], where Ct is the cycle threshold value defined as the fractional 
cycle number at which the target fluorescent signal passes a fixed threshold.  All 
experiments were performed in duplicates in three independent experiments and 
results are presented as means ± SE of replicates. 
 
2.12.  Collagen crosslinking 
Collagen 1 solution (StemCell Technologies, Inc., Vancouver, BC) was 
treated with TG2 (Sigma) in the presence of 1 mM dithiothreitol (DTT), 5 mM 
calcium chloride (CaCl2), and 100 mM Tris-HCl (pH 8.0), as previously described 
(Chau et al., 2005).  The collagen mixture was distributed into 96-well plate (50 µl 
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per well), incubated 90 min at 37°C with lid-on for crosslinking reaction, and dried 
overnight at 37°C with the lid-off.  
 
2.13.  Picrosirius red (PSR) staining 
Staining of paraffin-embedded slides used the PSR solution containing 0.1% 
of Direct red 80 powder (Sigma) dissolved in picric acid (Sigma) for 1 hour at 
room temperature.  Nuclei were stained with Weigert’s Hematoxylin (Sigma) for 
10 min.  The slides were washed twice in 0.5% glacial acetic acid and quickly 
dehydrated in ethanol and xylene to retain the birefringence of collagen.  Imaging 
with circular polarizing light used the Spot RT Color Carmera System 
(Diagnostics Instruments, Inc., Sterling Heights, MI) mounted on an inverted 
Nikon Diaphot 200 microscope (Nikon, Melville, NY). 
To quantify the proportion of differently colored collagen fibers, the 
MetaMorph software (Molecular Devices) was utilized.  Original 12-bit images 
were transformed to 24-bit images by separating colors to 8-bit RGB images and 
recombining into a 24-bit image.  The 24-bit images were resolved into the hue 
definitions as previously described (26); red 2-9 and 230-256, orange 10-38, 
yellow 39-51, and green 52-128.  The proportion of different colored collagen 
fibers were calculated by dividing the number of pixels within each hue range by 
the total number of pixels in all five different hue ranges and expressed as a 
percentage by multiplying 100.  The total collagen content in each image was 
quantified by dividing the total number of pixels in all five different hue ranges by 
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total pixels of the image and calculated to percentages.  The percentage of total 
collagen content in experimental group was normalized to control group to 
compare the total collagen content in two different groups. 
 
2.14.  Soluble collagen assay 
The amount of soluble collagen in pancreatic xenografts (n=6 per group) 
was determined by using the Sircol™ Soluble Collagen Assay kit (Biocolor Life 
Science Assays, Northern Ireland) according to manufacturer’s protocol.  Frozen 
tumors (n=6 per group) were homogenized on ice in an extraction buffer 
containing 50 mM Tris-HCl (pH7.4), 150 mM NaCl, and 0.5% NP40.  The 
homogenates were mixed by rotation for 2 hours at 4°C, followed by sonication 
on ice followed by 15 min of centrifugation.  Protein concentration was measured 
by Bradford assay, and 500 µg of total protein diluted into PBS were loaded into 
96-well plates and dried overnight at 37°C.  150 µl of Sircol dye reagent was 
added into each well and incubated for 1.5 hour at room temperature.  Excess 
dye was removed, and the plate was washed with 5% acidified water before 
solubilization in 150 µl of 0.1 M NaOH.  Absorbance was measured by 
BioPhotometer plus (Eppendorf, Hamburg, Germany) at a wavelength of 550 nm.  
Data are shown as the amount of soluble collagen (µg) present in 500 µg of total 
protein. 
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2.15.  Hydroxyproline assay 
The hydroxyproline colorimetric assay kit purchased from BioVison (Zurich, 
Switzerland; #K555-100) was used to measure the amount of total collagen in 
pancreatic xenografts.  For preparation of samples, frozen tumors (n=6 per group) 
were homogenized in 100 µl of dH2O for every 10 mg of tissue.  To each 100 µl 
of tissue homogenates, 100 µl of 12N HCl was added and hydrolyzed at 120°C 
for 3 hours with periodical mix by inverting.  To remove residue produced after 
the hydrolysis, the hydrolysates were vortexed and centrifuged at 10,000 x g for 
3 min.  From the supernatants of hydrolyzed samples, 20 µl was aliquoted to a 
96 well plate in duplicates and dried in 37°C oven overnight to remove residual 
HCl.  After the drying process, hydroxyproline standards were prepared on the 
same 96 well plate, generating concentrations of 0, 0.2, 0.4, 0.6, 0.8, and 1 
µg/well in duplicates.  For the reaction of the assay, 100 µl of Chloramine T 
reagent diluted in oxidation buffer was added to each sample and standard and 
incubated for 5 min at room temperature.  Then, 100 µl of DMAB concentrate 
diluted in perchloric acid/isopropanol solution was added to each well and 
incubated for 90 min at 60°C oven.  Absorbance was measured by 
SPECTRAmax® Plus 384 microplate spectrophotometer (Molecular Devices) at a 
wavelength of 560 nm. 
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2.16.  TG2 activity 
To determine the localization and enzymatic activity of cellular TG2, PDA 
cells and fibroblasts cultured on fibronectin (BD BioSciences) or collagen 
(StemCell Technologies) coated slides were incubated with 500 µM 5-
(Biotinamido) pentylamine (5-BP) (ThermoScientific) for 1 hour at 37°C.  After 
washing, cells were fixed with icy cold methanol for 10 min.  After blocking in 1% 
BSA, cells were incubated with Alexa Fluor® 647 streptavidin (Life Technologies) 
at a dilution of 1:500 for 1 hour. 
To assay in situ activity of TG2 in tumor tissue, 10 µm cryosections from 
pancreatic xenografts were dried for 20 min and blocked with 1% BSA.  Slides 
were then incubated at 37°C for 1.5 hour in a buffer containing 5 mM CaCl2, 100 
mM Tris-HCl (pH 8.0), in the presence or absence of 1 mM DTT, and 0.001 mM 
T26 or T26QN (negative control peptide), as previously described (Fukui et al., 
2013; K. B. Johnson et al., 2012; Yamane et al., 2010).  As another negative 
control, 5 mM EDTA was added to the buffer.  The TG2 enzymatic reaction was 
stopped by incubating with 25 mM EDTA for 5 min at room temperature.  The 
VECTASHIELD mounting medium contained DAPI (Vector Laboratories).  
Imaging used a LSM 510 META confocal multiphoton microscope system (Carl 
Zeiss, Inc.) under UV excitation at 647 nm for Alexa Fluor® 647 streptavidin, 488 
nm for FITC, and 405 nm for DAPI. 
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2.17.  Gemcitabine concentration measurement 
Gem concentrations in tumor tissue from the animal experiment were 
analyzed in the Pharmacology Core at Indiana University Simon Cancer Center 
(IUSCC, Dr. Jones - collaborator).  A sensitive and reproducible method was 
developed to quantify gemcitabine and 2’,2’ difluorodeoxyuridine (dFdU).  This 
method was used to quantify gemcitabine in plasma and xenografts. 
Tumors were harvested 2 min post intravenous gemcitabine injection and 
were homogenized in phosphate buffer containing tetrahydrouridine (THU), a 
cytidine deaminase inhibitor, to prevent the degradation of gemcitabine to dFdU.  
The method that was used to quantify gemcitabine and dFdU employed liquid-
liquid extraction, internal standardization (5-azacytidine) and HPLC-MS/MS.  A 
200 µl of tumor homogenized in THU containing phosphate buffer was extracted 
with ethyl acetate.  The tube was mixed, spun and the ethyl acetate layer was 
transferred to a separate tube.  The ethyl acetate was evaporated to dryness and 
reconstituted with mobile phase (acetonitrile: 5mM ammonium acetate).  An 
aliquot of the mobile phase was injected into the HPLC and the compounds were 
separated using a C8 column (5 um; 4.6 X 250 mm Zorbax).  The compounds 
were detected by ESI MS/MS in positive mode (Thermo Quantum Ultra; Thermo 
Fisher) using 264/112, 265/113, 245/113 as the Q1/Q3 for gemcitabine, dFdU, 
and 5-azacytidine, respectively.  The lower limit of quantification was 1 ng/ml and 
30 ng/ml for gemcitabine and dFdU, respectively. 
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2.18.  Statistical analysis 
Student's t test was used to compare measurements between groups.  P-
values < 0.05 were considered significant. 
 
2.19.  Immortalization of human pancreatic cancer associated fibroblasts 
This work was done with the help of Dr. Brittney-Shea Herbert at IUSM 
(Herbert, Hochreiter, Wright, & Shay, 2006). 
Preparation of hTERT retroviral vectors for transduction (done by 
Shay/Wright lab, UT-Southwestern): 
The human telomerase reverse transcriptase (hTERT) coding sequence 
was cloned into the pBabe retroviral vector containing a neomycin resistance 
gene.  Viral supernatants of empty or +hTERT vector were collected from the 
ecotropic PE501 packaging cell line after transfection and selection with 4 µg/ml 
of puromycin.  The ecotropic viral supernatants were used to infect the 
amphotrophic PA317 packaging cell line, followed by selection with 4 µg/ml of 
puromycin.  Then, the amphotropic viral supernatants from PA317 packaging cell 
line were collected, filtered through a 0.45 µm filter, and used to infect 
hpFibroblasts. 
Transduction of retroviral hTERT to hpFibroblasts: 
i) Isolation of hpFibroblasts:  Human primary pancreatic cancer associated 
fibroblasts (hpFibroblasts), F1071;  where F indicates fibroblasts and 1071 
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indicates IU pancreatic tissue bank patient number, were obtained from a PDA 
specimen collected from the operating room at IUSCC.  Briefly, human tumor 
tissue obtained from the operating room was minced and cultured on a culture 
dish until the fibroblasts proliferate and spread out.  The hpFibroblasts were 
collected by time difference of trypsinization between hpFibroblasts and other 
cells, as short time trypsinization detached only hpFibroblasts.  The third 
passage hpFibroblasts were used for immortalization.  
ii) Infection:  The third passage of hpFibroblasts was grown in 6-well plate until 
the cells were about 60% confluent.  Once the cells were ready, regular medium 
for hpFibroblasts (DMEM supplemented with 10% FBS and 1% antibiotics), 
supernatant containing retrovirus (hTERT and pLXSN) and polybrene (0.8 
mg/ml) were added.  The infecting medium (3ml), representing supernatant from 
retroviral packaging cells, was diluted into fresh regular medium (3ml) at a ratio 
of 1:1.  Polybrene was added into the diluted infecting medium at the final 
concentration of 4 µg/ml.  The hpFibroblasts were incubated overnight (15 hours) 
at 37°C under 5% CO2 with the infecting medium.  The next day, the infecting 
medium was replaced with 3ml of fresh medium, and the cells were incubated 8 
hours at 37°C under 5% CO2 for recovery.  The 2nd infection was followed for 
overnight incubation (15 hours) at 37°C under 5% CO2.  Next morning, the 
infecting medium was replenished to fresh regular medium, and the 
hpFibroblasts were grown until they became confluent (10 days).  
iii) Selection:  Once the cells were confluent, the infected hpFibroblasts were 
placed under selection with G418 at a final concentration of 200 µg/ml.  The 
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G418-selected hpFibroblasts were tested for telomerase activity by Amruta 
Phatak in Dr. Herbert’s laboratory, using Telomerase Repeat Amplification 
Protocol (TRAP) assay (Herbert et al., 2006).  
iv) Telomerase repeat amplification protocol (TRAP) assay:  For the TRAP 
assay, 10x104 cells of hpFibroblasts were collected. The cells were trypsinized 
and centrifuged at 3,000g for 5 min at room temperature. The supernatant was 
removed carefully, and the pellet was resuspended in icy cold NP40 lysis buffer 
(RNase-/DNase-free) which is composed of 10 mM Tris-HCl (pH 8.0), 1 mM 
MgCl2, 1 mM EDTA, 1% NP40 (v/v), 0.25 mM sodium deoxycholate, 10% 
glycerol (v/v), 150 mM NaCl, 5 mM β-mercaptoethanol, and 0.1 mM AEBSF, at 
the concentrations of 500 and 1,000 cells per µl.  A Cy5-labeled oligonucleotide 
primer for telomerase product was used for the PCR-based TRAP assay.  The 
PCR products were resolved on a polyacrylamide gel and visualized on a 
PhosphorImager using Image Quant software.  Relative telomerase activity was 
determined as the ratio of the intensity of the telomerase product bands to the 
internal standard control band. 
 However, this immortalized hpFibroblasts did not proliferate fast enough.  
Therefore, in this study, I alternatively used immortalized hpFibroblasts from Dr. 
Melissa Fishel at IUSM.  
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CHAPTER 3.  RESULTS 
3.1.  TG2 is abundantly expressed and enzymatically active in PDA cells 
and in the stroma of PDA tumors 
To determine the level of TG2 expression and subcellular localization in 
pancreatic tumors and in normal pancreas, IHC was performed.  We used 52 
clinically annotated human PDA specimens on a tissue microarray (TMA) from 
the IUSCC Tissue Bank.  Patient characteristics are presented in Table 4.  No 
TG2 immunostaining was recorded in the stroma of normal pancreas (n=3), and 
only faint (1+) staining was noted in normal ducts (Figure 10A).  In contrast, 
strong (2+ to 3+) TG2 cytoplasmic immunostaining was recorded in 36 out of 52 
(69%) specimens, supporting that TG2 expression is increased in PDA compared 
to normal duct epithelium (Figure 10B, upper left).  TG2 immunostaining was 
also recorded in the stroma of 44 out of 52 specimens, involving both the cellular 
(e.g. fibroblasts) as well as the extracellular compartments (84%, Figure 10B, 
upper right). 
To determine the enzymatic activity of TG2 in the stroma, 20 additional 
tumors, identified through the IUSCC Tissue Bank as PDA specimens associated 
with significant desmoplasia, were stained for TG2 and for isopeptide.  Isopeptide 
is a covalent ε-(γ-glutamyl)-lysine bond formed between the donor lysine residue 
of one protein and the acceptor glutamine residue of another protein as a result 
of TG2 mediated transamidation.  Concordant strong (2+ to 3+) TG2 and 
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isopeptide staining was recorded in 19 out of 20 additional specimens (Figure 
10B, lower), supporting that TG2 is expressed and active in the pancreatic DS.  
 
Table 4.  Clinical characteristics of PDA patients 
 
 
 
 
 
 
 
 
 
Figure 10.  TG2 is highly expressed and active in PDA cells and in the stroma of PDA 
tumors.  (A) Immunostaining for TG2 in normal pancreas (upper; 40X magnification, 
lower; 200X magnification).  (B) immunostaining for TG2 (upper) and isopeptide (lower) 
in PDA specimens (200X magnification). 
 
 
 
A. B. 
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3.2.  TG2 is secreted by PDA cells and localized in the PDA stroma 
First, to measure endogenous TG2 expression levels in HPNE, PDA, 
stellate cells, and fibroblasts, equal amount of cell lysates from each cell line was 
used for western immunoblotting (Figure 11).  Among four different PDA cell 
lines, AsPC1 and BxPC3 cells expressed relatively abundant TG2, and Panc1 
and Paca2 cells expressed relatively low TG2.  TG2 expression was also 
detectable in HPNE cells, but lower than in most PDA cell lines, confirming 
higher TG2 expression in PDA cells compared to normal pancreatic epithelial 
cells.  Interestingly, stellate cells and fibroblasts also expressed relatively high 
level of endogenous TG2, corresponding to the TG2 expression observed by IHC 
in the cellular compartment of the stroma of PDA specimens, mentioned in 
section 3.1. 
 
 
 
Figure 11.  TG2 expression in HPNE, PDA, stellate cells, and fibroblasts.  Western 
blotting for TG2 and GAPDH (internal control).  30 µg of protein per cell line were loaded. 
 
 
 
 
Next, to determine whether TG2 is secreted by PDA cells in the 
extracellular milieu, we measured TG2 expression by western blotting in 
conditioned media (CM).  For this, equal volume of CM collected from cell 
cultures were used for western blotting.  TG2 was detected in the CM collected 
from all PDA cells, confirming the secretion of TG2 by PDA cells (Figure 12). 
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Figure 12.  TG2 is secreted by PDA cells into the culture media.  Western blotting for 
TG2 in CM collected from PDA cells.  40 µl of CM per lane was loaded. 
 
 
 
 
In addition, TG2 secretion by PDA cells into the matrix was determined by 
using IF.  Extracellular TG2 was detectable in the matrix deposited by AsPC1, 
BxPC3, and Panc1 cells (Figure 13).  These data support the concept that PDA 
cells secrete TG2 into the ECM, implying the presence of secreted TG2 in the 
pancreatic tumor milieu.  
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Figure 13.  Detection of extracellular TG2.  IF for extracellular TG2 (Cy5, red) deposited 
by AsPC1, BxPC3, and Panc1 cells onto the collagen matrix.  Arrows point the TG2 
deposited in the ECM.  Nuclei are visualized by DAPI staining. 
 
 
 
 
To assess cellular localization and enzymatic activity of TG2, incorporation 
of 5-BP and T26 was utilized.  5-BP and T26 are known TG2 substrates, which 
incorporate into amine free proteins as a result of crosslinking activity of TG2. 
As shown in Figure 14, TG2 was abundantly expressed in the cytosol and 
on the plasma membrane of AsPC1 and Panc1 cells.  In addition, enzymatic 
activity of TG2 was detectable by incorporated 5-BP in the cytoplasm of both cell 
types.   
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However, TG2 was abundantly expressed, but was enzymatically inactive 
in fibroblasts (Figure 14 and Figure 15A) and in LP9 normal mesothelial cells 
(Figure 15B), suggesting that the enzymatic activity of TG2 may be differentially 
regulated in cancer vs. normal cells.  Specificity of the substrate incorporation 
assay is supported by lack of IF signal when cells were incubated with the mutant 
T26QN peptide (not a TG2 substrate, Figure 15B) or with EDTA (Figure 15A), a 
chelator of Ca2+.  
 
 
 
Figure 14.  TG2 is secreted into the pancreatic TME by PDA cells and is enzymatically 
active.  (A) Western blotting for TG2 and GAPDH (internal control) in PDA cells and 
fibroblasts.  (B) Western blotting for TG2 in CM (30µl/lane) collected from PDA cells.  (C) 
IF for TG2 (Alexa Fluor® 488, green) and 5-BP (Alexa Fluor® 647 Streptavidin, red) in 
AsPC1, Panc1 and NHF544 cells (600X magnification).  Nuclei are visualized by DAPI. 
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Figure 15.  TG2 is enzymatically active in PDA cells.  (A) IF staining for TG2 (Alexa 
Fluor® 488, green) and 5-BP (Alexa Fluor® 647 Streptavidin, red) in AsPC1 cells (600X 
magnification).  Incubation with 1 mM EDTA was used as a negative control (inhibits 
TG2 enzymatic activity).  Nuclei are visualized by DAPI staining.  (B) IF staining using 
FITC-labeled T26, and T26QN (negative control) in AsPC1 and LP9 mesothelial cells 
(600X magnification).  Nuclei are visualized by DAPI staining. 
 
A. 
B. 
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3.3.  TG2 knockdown in PDA cells 
To proceed with functional studies of TG2, TG2 was knocked down in 
AsPC1 and Panc1 cells by stably transducing shRNA targeting TG2 (shTG2).  
TG2 protein and mRNA expression levels were significantly downregulated in 
shTG2 transduced cells compared to cells transduced with scrambled shRNA 
(shCtrl, Figure 16A).  TG2 secretion in the CM was also decreased in shTG2 
compared to shCtrl transduced PDA cells (Figure 16B).  
 
 
 
 
 
 
 
Figure 16.  Knockdown of TG2 in PDA cells.  (A) TG2 expression measured by RT-PCR 
(left) and western blotting (right) in AsPC1 and Panc1 cells stably transduced with 
shRNA targeting TG2 (shTG2) or control shRNA (shCtrl).  (B) Western blotting for TG2 
in CM collected from AsPC1 +shCtrl and +shTG2 cells. 
 
 
 
 
3.4.  TG2 knockdown in PDA cells does not affect proliferation and colony 
formation, in vitro 
To determine the effect of TG2 knockdown on PDA cells, shRNA 
transduced PDA cell lines described in section 3.3 were used.  First, we 
A. 
B. 
< PCR > < Western Blotting > 
<	  Western	  Blotting	  >	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compared proliferation of PDA cells +shCtrl and +shTG2.  No significant 
difference in the proliferation was observed (Figure 17).  Next, we determined 
the ability to form colonies of PDA cells depending on TG2 expression level.  
Knockdown of TG2 in PDA cells did not inhibit the clonogenic potential compared 
to that of control cells (Figure 18).  Together, these results show that knockdown 
of TG2 in PDA cells does not directly affect cell proliferation and colony formation. 
 
 
 
Figure 17.  Effect of TG2 knockdown on PDA cell proliferation.  Proliferation of 
AsPC1+shCtrl and +shTG2 cells (left, CCK-8 assay) and of Panc1+shCtrl and +shTG2 
cells (right, BrdU assay).  Bars represent average measurements ± SE. 
 
 
 
 
 
 
Figure 18.  Effect of TG2 knockdown on PDA cell colony formation.  Clonogenic assay 
compares colony formation between AsPC1+shCtrl and AsPC1+shTG2 cells (left, n=3 
per group, p = 0.02) and Panc1+shCtrl and Panc1+shTG2 cells (right, n=3 per group, p 
= 0.14).  Bars represent average measurements ± SE;  * p < 0.05. 
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3.5.  TG2 knockdown in PDA cells inhibits tumor growth, in vivo 
To measure the effects of TG2 on tumor growth and metastasis, 
orthotopic human pancreatic cancer xenograft mouse model was generated by 
injecting PDA cells +shCtrl and +shTG2 (shown in section 3.3.) directly into the 
tail of pancreas of nude female mice.  Tumors were harvested at the 4th (AsPC1) 
and the 3rd (Panc1) week after PDA cell implantation, and used for the following 
analyses. 
The average tumor volume and weight were significantly decreased in 
xenografts derived from AsPC1+shTG2 cells compared to AsPC1+shCtrl cells 
(Figure 19A, left and middle panels, p = 0.02 and p = 0.04, respectively).  There 
was no significant difference in the number of macro-metastases visible and 
countable on the omentum and peritoneal surfaces between the two groups 
(Figure 19A, right panel, p = 0.70).  The stable knockdown of TG2 in 
AsPC1+shTG2 xenografts compared to controls was confirmed by IHC and was 
quantified by H scores (Figure 19B, p = 0.004), which was calculated as 
percentage of stained cells multiplied by intensity of staining (grade from 0 to 3+). 
Likewise, decrease in the average tumor volume and weight was 
observed in xenografts derived from Panc1+shTG2 cells compared to 
Panc1+shCtrl cells (Figure 20A, left and middle panels, p = 0.01 and p = 0.006, 
respectively).  The number of macro-metastases on the omentum and peritoneal 
surfaces was also significantly decreased in Panc1+shTG2 tumor bearing mice 
   69 
compared to controls (Figure 20A, right panel, p = 0.03).  Stable knockdown of 
TG2 was confirmed by IHC quantification (Figure 20B, p = 0.007). 
Interestingly, the effect of TG2 knockdown on decreased tumor growth 
and metastasis was more pronounced in tumors derived from Panc1 compared 
to AsPC1 cells.  This phenomenon is possibly due to the shorter doubling times 
of Panc1 cells (18±1 hours) vs. AsPC1 cells (24±1 hours) (Porcelli et al., 2013), 
which led to increased growth of Panc1+shCtrl tumors.  In addition, as Panc1 
cells express relatively low TG2 compared to AsPC1 cells, the effect of TG2 
knockdown in Panc1 cells may have been more prominent and remarkably 
inhibited Panc1+shTG2 tumor growth compared to AsPC1 tumors.  Taken 
together, these data demonstrate that TG2 expression levels in PDA cells are 
strongly correlated with tumor growth, in vivo. 
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Figure 19.  TG2 knockdown inhibits tumor growth in AsPC1 orthotopic xenograft mouse 
model.  (A) Average tumor volume (left, p = 0.02), weight (middle, p = 0.04), and number 
of metastases (right, p = 0.70) of xenografts derived from AsPC1+shCtrl (n=11) and 
+shTG2 (n=12) cells.  (B) IHC for TG2 in AsPC1+shCtrl and AsPC1+shTG2 xenografts 
(left).  Quantitated H scores of TG2 expression in tumors (right, n=10 per group, p = 
0.004).  * H score = percentage of stained cells x intensity of staining (grade from 0 to 
3+).  Bars represent average H scores ± SE;  * p < 0.05. 
 
 
 
 
 
 
 
 
 
 
A. 
B. 
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Figure 20.  TG2 knockdown inhibits tumor growth in Panc1 orthotopic xenograft mouse 
model.  (A) Average tumor volume (left, p = 0.01), weight (middle, p = 0.006), and 
number of metastases (right, p = 0.03) derived from Panc1+shTG2 and +shCtrl cells 
(n=7 per group).  (B) IHC for TG2 in Panc1+shCtrl and PanC1+shTG2 xenografts (left).  
Quantitated H scores of TG2 expression in tumors (right panels, n=3 per group, 
p=0.007). 
 
 
 
 
3.6.  TG2 is enzymatically active in PDA tumors 
 Under normal physiological conditions, TG2 is enzymatically inactive in 
vitro and in vivo.  Various stressors, such as injury or hypoxia, are required to 
activate TG2 (M. Siegel et al., 2008).  To determine whether TG2 is catalytically 
active in the pancreatic TME, we measured incorporation of the FITC-labeled 
T26 peptide, which is specifically crosslinked to ECM proteins by TG2 (K. B. 
Johnson et al., 2012).  Enzymatically active TG2 was detectable both intra- and 
extra-cellularly in AsPC1 and Panc1 xenograft tumor sections (Figure 21), 
suggesting that the enzyme is active in the pancreatic milieu.  Incubation with the 
A. 
B. 
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T26 peptide in the presence of EDTA and with the mutant T26QN peptide, which 
is not a TG2 substrate, were used as negative controls to prove specificity. 
 
 
 
Figure 21.  TG2 is enzymatically active in the PDA stroma.  IF using FITC-labeled T26, 
FITC-labeled T26 and EDTA (negative control), and T26QN (negative control) in AsPC1 
and Panc1 xenografts (200X magnification). 
 
 
 
 
 In addition, according to Jin et al., extracellular TG2 is catalytically inactive 
even in open, active conformation due to oxidation between the Cys residues in 
the catalytic core.  Therefore, reducing agents, such as DTT or thioredoxin, are 
needed to activate TG2 (Jin et al., 2011). 
 To exclude the possibility that TG2 might be artificially activated by DTT 
during the assay, we incubated T26 in the absence of DTT in the reaction buffer.  
Enzymatic activity of TG2 was detectable in the PDA xenografts even in the 
absence of DTT (Figure 22), supporting that TG2 is enzymatically active, in situ. 
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Figure 22.  TG2 is enzymatically active, in situ, in the PDA xenografts.  IF using FITC-
labeled T26, in the presence and the absence of 1 mM DTT in Panc1 xenografts (200X 
magnification). 
 
 
 
 
3.7.  Enzymatically active TG2 crosslinks collagen in PDA tumors 
 One of the known TG2 substrates is collagen I, a critical component of the 
pancreatic DS (Mahadevan & Von Hoff, 2007).  To determine whether collagen I 
was crosslinked by TG2 in the pancreatic TME, we used PSR staining which 
distinguishes the thickness of collagen fibers.  Birefringence of PSR staining 
under polarizing microscope is highly specific for collagen fibers, which appear 
red, orange, yellow, or green in order of decreasing thickness (Rich & Whittaker, 
2005).   
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 Birefringence of collagen fibers in AsPC1+shCtrl tumors was mostly bright 
orange, red, and yellow, while that in AsPC1+shTG2 tumors was mostly green 
and yellow (Figures 23A), suggesting that collagen I fibers are thicker in tumors 
derived from TG2 expressing cancer cells.  Moreover, the area of birefringence 
corresponding to collagen was more extensive in AsPC1+shCtrl tumors 
compared to AsPC1+shTG2 xenografts (Figure 23B, p = 0.001), demonstrating 
increased collagen deposition in TG2 expressing tumors.  As shown in Figure 23, 
most collagen was deposited around pancreatic ducts and at the edge of tumors.  
Likewise, Panc1+shCtrl tumors also contained higher proportion of thicker 
collagen compared to Panc1+shTG2 tumor.  However, overall birefringence of 
collagen in Panc1 tumors was less than in AsPC1 tumors (data not shown). 
 To verify that this correlation is relevant to human pancreatic tumors, PSR 
staining of high-TG2 and low-TG2 PDA specimens was carried out (n=6 per 
group).  First, IHC of TG2 was perfomed on a human pancreatic cancer TMA, 
and the specimens were grouped into high-TG2 and low-TG2 expressing groups 
based on H scores.  The same TMA was stained with PSR, and collagen 
thickness was analyzed based on different birefringence colors.  Then, the 
correlation of TG2 expression level and crosslinked collagen content was 
compared.  Likewise, the proportion of red and orange birefringence was 
significantly higher in high-TG2 tumor, while that of yellow and green was 
significantly higher in low-TG2 tumors (Figure 24A, p < 0.001).  These data 
suggest that TG2 expression levels are strongly correlated with the percentage of 
crosslinked collagen.  Moreover, the area of birefringence corresponding to 
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collagen was more extensive in high-TG2 tumors compared to low-TG2 tumors 
(Figure 24B, p = 0.001). 
 
 
 
 
 
 
Figure 23.  Enzymatically active TG2 crosslinks collagen in the PDA stroma.  (A) 
Representative PSR staining determines thickness of collagen fibers in AsPC1+shCtrl 
and AsPC1+shTG2 tumors (left);  upper - bright field transmission (BFT) microscopy, 
lower - polarizing light microscopy (200X magnification).  Quantification of collagen fiber 
thicknesses based on differences in birefringence in AsPC1+shCtrl and AsPC1+shTG2 
xenografts (right).  (B) Quantitative assessment of collagen content based on the area of 
collagen birefringence per microscopic field.  Bars represent average fold changes ± SE;  
n=11 images per group, p < 0.001.   
 
 
 
 
B. 
A. 
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Figure 24.  Higher expression level of TG2 is correlated with higher percentage of 
crosslinked collagen in human PDA specimens.  (A) Representative PSR staining 
determines thickness of collagen fibers in high-TG2 and low-TG2 tumors (left);  upper - 
IHC for TG2 (100X magnification), lower - polarizing light microscopy (200X 
magnification).  Quantification of collagen fiber thicknesses based on differences in 
birefringence in high-TG2 and low-TG2 PDA specimens (right).  (B) Quantitative 
assessment of collagen content based on the area of collagen birefringence per 
microscopic field.  Bars represent average fold changes ± SE;  n=6 images per group, p 
< 0.0001. 
 
 
 
 
 To measure the amount of non-crosslinked, soluble collagen in the 
pancreatic xenografts derived from +shCtrl and +shTG2 PDA cells, sircol soluble 
collagen assay was performed using protein extracts from the xenografts.  
Soluble collagen content was significantly higher (p = 0.001) in AsPC1+shTG2 
A. 
B. 
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compared to AsPC1+shCtrl tumors (Figure 25, left, n=6 per group) and in 
Panc1+shTG2 compared to Panc1+shCtrl xenografts (Figure 25, right, p = 
0.005, n=6 per group).  These data add to the observations that TG2 secreted 
from PDA cells promotes collagen crosslinking reaction in the pancreatic stroma. 
 
 
 
Figure 25.  Soluble collagen measured by the Sircol assay in AsPC1+shCtrl (n=6) and 
AsPC1+shTG2 (n=5, left, p = 0.001) and Panc1+shCtrl and Panc1+shTG2 tumors (n=6 
per group, right, p = 0.005).  Bars represent average measurements of the groups ± SE.  
* denotes p < 0.05. 
 
 
 
 
Additionally, to measure the total collagen content in the AsPC1+shCtrl 
and AsPC1+shTG2 xenografts, hydroxyproline assay was used.  Hydroxyproline 
is a major component of collagen, and its distribution is highly restricted to 
collagen. Therefore, hydroxyproline content reflects amount of collagen in the 
sample.  The amount of hydroxyproline present in the hydrolysates of 
AsPC1+shCtrl and +shTG2 was similar, demonstrating no difference in the 
amount of total collagen between AsPC1+shCtrl and AsPC1+shTG2 xenografts 
(Figure 26).  
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Collectively, these data suggest that TG2 secreted from PDA cells 
promotes collagen crosslinking reaction in PDA tumors. 
 
 
 
Figure 26.  Total collagen content is the same in pancreatic xenografts derived from 
control and TG2 knocked down PDA cells.  Hydroxyproline assay measures collagen 
content in the hydrolysates of AsPC1+shCtrl and +shTG2 xenografts (n=6 per group, p > 
0.9).  20 µl from 200 µl of hydrolysate was used for the assay.  Bars represent average 
measurements ± SE. 
  
 
 
 
3.8.   TG2-mediated crosslinked collagen promotes proliferation of 
fibroblasts 
To determine the functional significance of native and TG2-mediated 
crosslinked collagen to the proliferation of fibroblasts, NHF544 fibroblasts were 
grown on plates with no vs. native collagen and native vs. TG2-mediated 
crosslinked collagen.  The proliferation of NHF544 fibroblasts, measured by 
CCK-8 assay, was increased on collagen coated compared to uncoated plates 
(Figure 27, left panel, p < 0.04) and even more on TG2-mediated crosslinked 
collagen compared to native collagen (Figure 27, right panel, p < 0.03).   
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Figure 27.  Proliferation of fibroblasts is promoted by collagen and furthermore by TG2-
mediated crosslinked collagen.  CCK-8 assay measures proliferation of NHF544 
fibroblasts grown on collagen coated or uncoated plates (left, p < 0.04) and on native or 
TG2-mediated crosslinked collagen (right, p < 0.03).  Bars represent average 
measurements ± SE. 
 
 
 
 
Likewise, the proliferation of immortalized human PDA-associated 
fibroblasts (hpFibroblasts) was augmented on collagen coated compared to 
uncoated plates (Figure 28, left panel, p = 0.01) and furthermore on TG2-
mediated crosslinked collagen compared to native collagen (Figure 28, right 
panel, p < 0.001). 
Taken together, these data suggest that collagen and crosslinked collagen 
in the matrix promote fibroblast proliferation.  
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Figure 28.  Proliferation of hpFibroblasts is promoted by collagen and furthermore by 
TG2-mediated crosslinked collagen.  CCK-8 assay measures proliferation of 
hpFibroblasts cultured on collagen coated or uncoated plates (left, p = 0.01) and on 
native or on TG2-mediated crosslinked collagen (right, p < 0.001).  The proliferation 
assay was performed 48 hours after the cell culture.  Bars represent average 
measurements ± SE.  hpFibroblasts were obtained and provided by Dr. Melissa Fishell 
at IUSM. 
 
 
 
 
3.9.  TG2 expressing PDA cells promote proliferation of fibroblasts 
Next, to study the effect of TG2 secreted by PDA cells on stromal cell 
proliferation, co-culture experiments were performed.  GFP-expressing human 
normal dermal fibroblasts (GFP-HNDFs) were co-cultured with AsPC1+shCtrl or 
+shTG2 cells, and the proliferation of fibroblasts was determined by measuring 
green fluorescence emitted from the fibroblasts.  The direct co-culture of GFP-
HNDFs with TG2 expressing AsPC1 cells significantly promoted proliferation of 
the fibroblasts over a 14-day period compared to the co-culture with 
AsPC1+shTG2 cells (Figure 29, p < 0.03).  The proliferation of fibroblasts in co-
culture with cancer cells expressing and secreting low levels of TG2 
(AsPC1+shTG2) was not different from proliferation of fibroblasts cultured alone, 
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suggesting that secretion of TG2 in co-culture models augments the fibrotic 
response.   
 
 
 
Figure 29.  TG2 expressing PDA cells promote proliferation of fibroblast in a co-culture.  
Proliferation of GFP-HNDFs in co-culture with AsPC1+shCtrl or AsPC1+shTG2 cells or 
grown alone for 14 days (p < 0.03).  Green fluorescence was measured at Ex. 485nm 
and Em. 538nm. 
 
 
 
 
To determine the direct effect of TG2 on stromal cell proliferation, different 
concentrations (0, 1, and 2.5 µg/ml) of wild-type (active) and mutant (C277S; 
inactive) recombinant TG2 were added into the growth medium of stromal cells in 
the absence of PDA cells.  In contrast to the co-culture results, active 
recombinant TG2 did not alter fibroblast or stellate cell proliferation (Figure 30), 
measured by BrdU assay.  These results suggest that TG2 acts in concert with 
other factors in the matrix produced by PDA cells to stimulate fibroblasts 
proliferation.  
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Figure 30.  Externally added recombinant TG2 does not alter proliferation of fibroblast 
and mouse pancreatic stellate cells (mPSCs).  BrdU assay measures proliferation of (A) 
NHF544 and (B) mPSCs treated for 48 hours with various concentrations (0, 1, and 2.5 
µg/ml) of purified recombinant TG2 (active) and mutant C277S TG2 (inactive) (n=3 per 
group, p > 0.3).  Bars represent average measurements ± SE. 
 
 
 
 
3.10.  TG2 expressing PDA cells activate fibroblasts 
To determine whether fibroblasts are activated in the presence of PDA 
cells, co-culture experiments were performed, followed by IF for α-SMA, a marker 
for active fibroblasts.  Co-culture of NHF544 cells with AsPC1 and Panc1 cells 
caused increased expression of α-SMA in fibroblasts (Figure 31A). 
B. 
A. 
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As we observed activation of fibroblasts in the presence of PDA cells, and 
as activation of fibroblasts is known to promote collagen production, we next 
determined whether TG2 secreted by PDA cells contributes to fibroblast 
activation.  To assess the significance of TG2 to fibroblast activation, NHF544 
fibroblasts were co-cultured with +shCtrl and +shTG2 PDA cells, and collagen 
deposition by fibroblasts was analyzed by IF.  Increased collagen I staining was 
observed in NHF544 fibroblasts when co-cultured with TG2 expressing AsPC1 
and Panc1 control (+shCtrl) cells, compared to fibroblasts co-cultured with 
AsPC1 and Panc1 +shTG2 cells (Figure 31B). 
In addition, activated fibroblasts were measured in vivo in AsPC1+shCtrl 
or AsPC1+shTG2 xenografts by IHC for α-SMA and were quantified by H score.  
The number of α-SMA expressing, activated fibroblasts was significantly higher in 
AsPC1+shCtrl compared to +shTG2 xenografts (Figure 32, p < 0.05). 
Collectively, these data show that in the pancreatic TME, TG2 secreting 
PDA cells promote the growth, the activation, and the collagen deposition by 
fibroblasts. 
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Figure 31.  TG2 activates fibroblasts promoting collagen production.  (A) IF for α-SMA 
(Alexa Fluor® 488, green) in NHF544 cultured alone (left) or co-cultured with AsPC1 
(middle) or Panc1 cells (right).  (B) IF for collagen I (Cy5, red) in NHF544 co-cultured 
with AsPC1+shCtrl or +shTG2 (left) or with Panc1+shCtrl and +shTG2 cells (right).  
Nuclei are visualized by DAPI (600X magnification).  
A. 
B. 
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Figure 32.  TG2 activates fibroblasts in mouse PDA xenografts.  IHC for α-SMA 
identifies activated fibroblasts in AsPC1+shCtrl (n=10) and +shTG2 (n=7) xenografts 
(left).  H scores quantify fibrosis (right, p < 0.05). Bars represent average quantification ± 
SE.  * denotes p < 0.05. 
 
 
 
 
3.11.  Collagen and stromal cells promote growth of PDA cells 
 Next, we tested whether stromal alterations induced by TG2 conversely 
regulate the growth of PDA cells.  First, the proliferation of PDA cells grown on 
collagen-coated vs. uncoated plates was measured by using the BrdU assay.  
The proliferation of AsPC1 and Panc1 cells was promoted when cells were 
cultured on collagen-coated plates compared to uncoated (Figure 33A, p < 0.03). 
In addition, proliferation of PDA cells grown on feeder layer of hPSCs vs. 
no feeder layer was analyzed by using crystal violet staining.   The proliferation of 
PDA cells grown on hPSC feeder layer was enhanced compared to when they 
were cultured without feeder layer (Figure 33B, p < 0.006). 
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Figure 33.  Collagen and stromal cells promote proliferation of PDA cells.  (A) BrdU 
assay measures proliferation of AsPC1 and Panc1 cells grown on collagen-coated or 
uncoated plates (p < 0.03).  (B) Crystal violet staining measures proliferation of AsPC1 
and Panc1 cells cultured on a feeder layer of hPSCs or without feeder layer (p < 0.006).  
Bars represent average of 4 replicate measurements for each group ± SE.  * denotes p < 
0.05.  
 
 
 
 
Taken together, these results demonstrate that TG2 secreted by PDA 
cells in the tumor milieu modulates the PDA stroma by promoting activation, 
proliferation, and collagen deposition of fibroblast and by crosslinking collagen.  
These stromal modifications conversely promote proliferation of PDA cells and 
provide a supportive environment for continuing tumor growth. 
 
3.12.  Knockdown of TG2 in PDA cells decreased proliferation, in vivo 
 Based on our findings showing that 1) pancreatic tumors contain activated 
stromal cells and crosslinked collagen, 2) those tumor components promote PDA 
cell proliferation in vitro, and 3) knockdown of TG2 in PDA cells decreases tumor 
growth in vivo, but 4) does not affect PDA cell proliferation and colony formation 
in vitro, we wanted to determine whether knockdown of TG2 in PDA cells has an 
A. B. 
   87 
effect on PDA cell proliferation in vivo.  To assess this, IHC staining for Ki67, a 
marker for proliferation, on pancreatic xenografts derived from AsPC1+shCtrl or 
AsPC1+shTG2 cells was performed.  Proliferation of PDA cells in the xenografts 
was quantified by counting the Ki67 positive PDA cells in five randomly chosen 
fields per sample. 
 Interestingly, in contrast to the in vitro result, which showed no effect of 
TG2 knockdown on PDA cell proliferation, the number of Ki67 positive PDA cells 
in AsPC1+shTG2 xenografts was significantly decreased, in vivo, compared to 
that of controls (Figure 34). 
Taken altogether, our findings demonstrate that the effects of TG2 on 
tumor growth are not due to the direct effects on PDA cells, but by the combined 
TG2 effects on the PDA stroma, which in turn regulate PDA cell proliferation and 
tumor progression. 
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Figure 34.  Knockdown of TG2 in PDA cells decreased proliferation in vivo.  IHC stains 
for Ki67 in AsPC1+shCtrl and +shTG2 xenografts (upper).  Graph represents relative 
percentage of Ki67 positive cells in AsPC1+shCtrl and +shTG2 xenografts (lower; n=3 
per group, p = 0.042).  Five randomly selected fields per sample were analyzed for Ki67 
positive cells.  
 
 
 
 
3.13.  Matrix induced YAP/TAZ activation promotes PDA cell proliferation 
As the pancreatic stroma becomes infiltrated by crosslinked collagen and 
activated fibroblasts, its stiffness increases.  A mechanism activated by the 
physical properties of the ECM is the process of mechanotransduction, which 
translates mechanical stimuli into biochemical signals.  The major factors 
activated by mechanical cues are the Yes-associated protein (YAP) and the 
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transcriptional co-activator with PDZ-binding motif (TAZ), which in turn regulate 
cancer cell growth.  YAP and TAZ are known transcription factors involved in the 
Hippo signaling pathway.  Activation of Hippo signaling pathway via MST1/2 and 
LATS1/2 kinases phosphorylates YAP (p-YAP), which becomes inactive and 
undergoes proteosomal degradation (B. Zhao, Li, Lei, & Guan, 2010).  However, 
when Hippo signaling pathway is switched off, non-phosphorylated, active YAP 
translocates into the nucleus and promotes its target gene expression leading to 
cell proliferation. 
However, besides the role of YAP and TAZ in Hippo signaling pathway, 
Dupont et al. have reported that YAP and TAZ are also involved in 
mechanotransduction, which proceeds independently of the Hippo signaling 
pathway (Dupont et al., 2011).  They have shown that cells can be affected by 
the stiffness of the ECM via YAP and TAZ activation.  Activated YAP and TAZ in 
a stiff environment translocate into the nucleus and promote cell proliferation, 
while inactive YAP and TAZ in cells embedded in a soft matrix remain in the 
cytoplasm. 
On the basis of the report by Dupont et al., we determined the effect of 
collagen on YAP/TAZ activation in PDA cells.  First, we determined cellular 
localization of YAP/TAZ in PDA cells grown on collagen-coated vs. uncoated 
plates by using IF.  We noted increased nuclear YAP/TAZ localization in Panc1 
and AsPC1 cells plated on collagen-coated plates compared to uncoated plates 
(Figure 35A and 35B), indicating that higher proportion of YAP/TAZ is activated 
in PDA cells when cultured on collagen vs. no collagen. 
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Figure 35.  Collagen increases nuclear localization of YAP/TAZ in PDA cells.  (A) IF for 
YAP/TAZ (Alexa Fluor® 488, green) in Panc1 and AsPC1 cells grown on collagen-coated 
or uncoated slides (600X magnifications).  (B) Pie charts show the relative percentage of 
nuclear YAP/TAZ in Panc1 and AsPC1 cells plated on collagen-coated or uncoated 
plates.  Nuclear localization of YAP/TAZ in PDA cells was quantified by averaging the 
intensity of green fluorescence in the nucleus of each cell, which was analyzed via 
MetaMorph software. 
 
 
 
 
Next, we analyzed p-YAP (inactive) level in PDA cells grown on collagen-
coated vs. uncoated plates by using western blotting.  Decreased levels of p-YAP 
and increased ratio of total-YAP/p-YAP were detected in PDA cells plated on 
collagen-coated compared to uncoated plates (Figure 36), confirming the IF 
result that YAP is activated in PDA cells when cultured on collagen vs. no 
collagen.   
A. 
B. 
A. 
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Figure 36.  Collagen decreases phosphorylation of YAP in PDA cells.  Western blotting 
(upper) shows total-YAP and p-YAP in Panc1 and AsPC1 cells plated on collagen-
coated or uncoated plates and bars (lower) represent the ratio of total-YAP/p-YAP.  
 
 
 
 
Collectively, these data suggest that YAP/TAZ transcription factors are 
activated in PDA cells by the presence of collagen matrix, and also possibly by 
the collagen matrix, which has become stiff due to the collagen crosslinking by 
TG2 secreted from PDA cells.  
Based on the possibility that TG2, secreted by PDA cells, crosslinks and 
renders the collagen matrix stiff, we next determined the involvement of TG2 to 
YAP/TAZ activation in PDA cells grown on collagen.  Panc1+shCtrl and +shTG2 
and AsPC1+shCtrl and +shTG2 cells were cultured on collagen-coated slides.  
First, IF was used to visualize cellular localization of YAP/TAZ in PDA cells 
±shTG2 plated on collagen.  Increased nuclear localization was recorded in TG2 
expressing control Panc1 and AsPC1 cells compared to +shTG2 PDA cells 
(Figure 37A and 37B), suggesting that TG2 is involved in activation of YAP/TAZ 
in PDA cells grown on collagen.  
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Figure 37.  TG2 increases nuclear localization of YAP/TAZ in PDA cells grown on 
collagen.  (A) IF for YAP/TAZ (Alexa Fluor® 488, green) in Panc1+shCtlr and +shTG2 
and AsPC1+shCtrl and +shTG2 cells grown on collagen (600X magnification).  (B) Pie 
charts show the relative percentage of nuclear YAP/TAZ in Panc1+shCtrl and +shTG2 
cells grown on collagen.  Nuclear localization of YAP/TAZ in PDA cells was quantified by 
averaging the intensity of green fluorescence in the nucleus of each cell, which was 
analyzed via MetaMorph software. 
 
 
 
 
Next, we measured p-YAP in PDA cells ±shTG2 plated on collagen by 
using western blotting.  Decreased levels of p-YAP and increased ratio of total-
YAP/p-YAP were observed in Panc1+shCtrl compared to +shTG2 cells (Figure 
38), confirming IF result that TG2 is involved in activation of YAP/TAZ in PDA 
cells cultured on collagen.  
A. 
B. 
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Figure 38.  TG2 decreases phosphorylation of YAP in PDA cells grown on collagen.  
Western blotting (left) shows total-YAP and p-YAP in Panc1+shCtrl or Panc1+shTG2 
grown on collagen.  Bars (right) represent the ratio of total-YAP/p-YAP.   
 
 
 
 
Next, to determine whether nuclear localization of YAP/TAZ corresponds 
to increased transcriptional activity, we measured the transcriptional activity of 
YAP in Panc1 cells cultured on collagen by using the TEAD4 reporter assay.  
TEAD4 reporter assay is processed through production of Gal4-TEAD4 fusion 
protein, which recruits YAP to the promoter of firefly luciferase reporter resulting 
in induction of luciferase expression.  Therefore, high luminescent signal will be 
detected in the presence of YAP/TAZ, while no signal will be detected in the 
absence of YAP/TAZ.  Luciferase activity in TEAD4 reporter assay was 
increased in Panc1+shCtrl compared to Panc1+shTG2 cells cultured on collagen 
(Figure 39, p = 0.009), confirming the activation of YAP/TAZ in TG2 expressing 
cells.  
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Figure 39.  TG2 activates YAP in PDA cells grown on collagen.  TEAD4 reporter assay 
in Panc1+shCtrl and Panc1+shTG2 cells grown on collagen (n=5, p = 0.009).  Firefly 
luciferase activity was normalized to renilla luciferase.  Bars represent averages of 5 
replicates per group ± SE;  * denotes p < 0.05.   
 
 
 
 
The activation of YAP/TAZ results in up-regulation of specific target genes.  
To assess YAP/TAZ transcriptional activity, we measured the mRNA levels of 
connective tissue growth factor (CTGF), which is a known YAP/TAZ target gene, 
by utilizing qRT-PCR.  Increased CTGF mRNA level (Figure 40, p = 0.04) was 
observed in Panc1+shCtrl cells compared to Panc1+shTG2 cells grown on 
collagen, confirming activation of YAP/TAZ in TG2 expressing cells.  
 
 
 
Figure 40.  Activation of YAP/TAZ promotes expression of CTGF gene in PDA cells 
grown on collagen.  QRT-PCR measures CTGF mRNA levels in Panc1+shCtrl and 
Panc1+shTG2 cells grown on collagen (p = 0.04).  Bars represent average fold changes 
± SE.  * denotes p < 0.05. 
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 Collectively, these data suggest that TG2 expressed in PDA cells is 
involved in activation of YAP and TAZ in PDA cells grown on collagen matrix, 
possibly by crosslinking collagen and increasing the environment stiffness.  
Further studies focused on measurement of collagen matrix stiffness are needed 
to delineate the specific mechanism by which TG2 activates YAP/TAZ.  
Lastly, to determine the significance of YAP and TAZ to PDA cell 
proliferation, transient knockdown of YAP and TAZ was performed by 
transfecting siRNA targeting both transcription factors.  First, knockdown of YAP 
and TAZ in PDA cells by siRNAs was confirmed by western blotting (Figure 41). 
 
 
 
Figure 41.  Knockdown of YAP/TAZ in PDA cells by transient siRNA transfection.  
Western immunoblotting for YAP and TAZ in AsPC1 and Panc1 cells transfected with 
siRNA targeting YAP and TAZ.  GAPDH served as a loading control. 
 
 
 
 
Next, we measured proliferation of control (+siCtrl) and +siYAP/TAZ PDA 
cells by performing BrdU assay.  Knockdown of YAP/TAZ decreased proliferation 
of PDA cells compared to control cells grown on collagen (Figure 42, p < 0.01), 
confirming that YAP and TAZ are important players involved in cell proliferation.  
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Figure 42.  Knockdown of YAP/TAZ in PDA cells decreases cell proliferation.  BrdU 
assay measures proliferation of AsPC1 (left) and Panc1 (right) cells transfected with 
siRNA targeting YAP and TAZ (n=4 per group, p < 0.01).  Bars represent average of 4 
replicates ± SE;  * denotes p < 0.05. 
 
 
 
 
Taken together, these data demonstrate that the transcription factors, YAP 
and TAZ, are activated in TG2 expressing PDA cells grown on collagen, and that 
their activation regulates cell proliferation.  These findings outline a new 
mechanism by which cancer cell proliferation is modulated by TG2 through 
signals reflected from the tumor cells into the surrounding stroma. 
 
3.14.  Effect of TG2 knockdown on response to gemcitabine in PDA cells 
and in tumors 
3.14.1.  Knockdown of TG2 does not affect response to gemcitabine in PDA 
cells, in vitro 
To determine whether knockdown of TG2 in PDA cells alters sensitivity of 
PDA cells to gemcitabine, AsPC1+shCtrl or +shTG2 cells (Figure 16) were 
treated with gemcitabine in dose-dependent manner for 48 hours, and the 
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number of proliferating, live cells was quantified by CCK-8 assay.  The number of 
surviving AsPC1+shTG2 cells after gemcitabine treatment was not different from 
that of AsPC1+shCtrl cells (Figure 43), suggesting that the knockdown of TG2 
does not sensitize PDA cells to gemcitabine. 
In addition, proliferation of both AsPC1+shCtrl and +shTG2 cells was 
constant at the IC50 level in the presence of gemcitabine (Figure 43), indicating 
that gemcitabine blocks cell proliferation, consistent with its known mechanism of 
action (Shipley et al., 1992). 
 
 
 
Figure 43.  Knockdown of TG2 does not affect response to gemcitabine in PDA cells.  
CCK-8 assay measures proliferation of AsPC1+shCtrl and +shTG2 cells after 48 hours 
of gemcitabine treatment in dose-dependent manner (1-100 µM).  Bars represent 
average fold changes of triplicates ± SE. 
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3.14.2.  Co-culture of PDA cells with fibroblasts decreases sensitivity of 
PDA cells to gemcitabine, in vitro 
As we have observed 1) increased proliferation of PDA cells cultured on a 
feeder layer of stromal cells and 2) dense PDA stroma with active stromal cells, 
we hypothesized that fibroblasts could protect PDA cells from gemcitabine, 
leading to continuous proliferation of PDA cells. 
To test this, we performed co-culture of GFP-expressing AsPC1 cells with 
NHF544 fibroblasts at a ratio of 1:1.  Proliferation of AsPC1 cells was determined 
by measuring green fluorescence emitted from the AsPC1 cells during the 96-
hour time course.  As shown in Figure 44, AsPC1 cells proliferated more when in 
co-culture with fibroblasts compared to AsPC1 cells cultured alone (left, p < 
0.05). 
In addition, 96-hour gemcitabine treatment at a high concentration (200 
µM) in the co-culture of AsPC1 with fibroblasts did not attenuate the proliferation 
of AsPC1 cells during the 96-hour time course.  On the other hand, the number 
of surviving AsPC1 cells was decreased in the presence of gemcitabine when 
cultured alone, consistent with the known anti-proliferative effects of gemcitabine 
(Figure 44, right, p < 0.05). 
Overall, these data suggest that fibroblasts present in the co-culture 
protect PDA cells from the effects of gemcitabine. 
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Figure 44.  Fibroblasts protect PDA cells from gemcitabine treatment.  Proliferation of 
AsPC1+GFP cells in co-culture with fibroblasts or grown alone (left) and treated with 
gemcitabine (right) for 4 days.  Green fluorescence in AsPC1+GFP cells was measured 
at Ex. 485nm and Em. 538nm.  Bars represent average RFUs of triplicates ± SE.  * 
denotes p < 0.05. 
 
 
 
 
3.14.3.  Knockdown of TG2 in PDA cells inhibits tumor growth and 
sensitizes tumors to gemcitabine 
 Based on our previous results showing decreased fibrosis in shTG2 PDA 
cell-derived xenografts and decreased sensitivity to gemcitabine in PDA cells 
when co-cultured with stromal cells, we tested whether knockdown of TG2 in 
PDA cells induces sensitivity to gemcitabine in PDA tumors.  To test this, we 
used orthotopic pancreatic xenograft mouse model derived from AsPC1+shCtrl 
or +shTG2 cells, treated with gemcitabine twice a week for 4 weeks at a dose of 
25 mg/kg via intraperitoneal injection (n=7 per PBS group and n=8 per 
gemcitabine group). 
 In concordance with previous data, average tumor volumes and weights 
were significantly decreased in xenografts derived from AsPC1+shTG2 cells 
compared to controls (Figure 45, upper, p = 0.002 and p = 0.001, respectively), 
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while there was no significant difference in the number of macro-metastases 
between the two groups (Figure 45, lower, p = 0.55). 
Gemcitabine treatment decreased the average tumor size and weight in 
both AsPC1+shCtrl and AsPC1+shTG2 derived xenografts compared to PBS 
(Figure 45, upper, p < 0.002).  Furthermore, average tumor size and weight were 
significantly lower in AsPC1+shTG2 derived xenografts treated with gemcitabine 
compared to controls treated with gemcitabine (Figure 45, upper, p = 0.04 and p 
= 0.03, respectively). 
In addition, treatment of gemcitabine in mice bearing AsPC1+shTG2 
xenografts significantly decreased number of macro-metastasis compared to 
mice carrying AsPC1+shCtrl tumors (Figure 45, lower, p = 0.005).  Together, 
these data suggest that the knockdown of TG2 inhibits tumor growth and 
sensitizes tumors to gemcitabine, in vivo. 
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Figure 45.  Knockdown of TG2 in PDA cells decreases tumor growth and sensitizes 
tumors to gemcitabine.  Average tumor volume, weight, and number of metastases of 
xenografts derived from AsPC1+shCtrl and +shTG2 cells and treated with gemcitabine 
or PBS.  n=7 per PBS groups and n=8 per gemcitabine groups.  Bars represent average 
measurements ± SE;  * denotes p < 0.05. 
 
 
 
 
3.14.4.  Knockdown of TG2 in PDA cells does not affect penetrance of 
gemcitabine in tumor tissues 
 Based on our findings showing decreased fibrosis in shTG2 tumors, we 
hypothesized that the more pronounced gemcitabine effects in shTG2 tumors is 
due to increased penetrance of gemcitabine in the shTG2 tumors compared to 
control tumors.  To determine the gemcitabine concentrations in tumor tissues 
depending on TG2 expression levels, we used orthotopic pancreatic xenograft 
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mouse model derived from AsPC1+shCtrl and +shTG2 cells.  After 4 weeks of 
PDA cell implantation, the mice were given a single dose of gemcitabine (25 
mg/kg) via intravenous injection and tumors were harvested within 2 minutes.  
The uptake of gemcitabine in pancreas occurs within minutes after intravenous 
administration, and gemcitabine is rapidly excreted (Kristjansen, Brown, Shipley, 
& Jain, 1996; Shipley et al., 1992), justifying the time point chosen.  
Concentrations of gemcitabine and its derivative, 2’,2’-difluorodeoxyuridine 
(dFdU), in tumor tissues were quantified by HPLC-MS/MS [collaboration with Dr. 
Jones in the pharmacology core at IUSCC]. 
 The sum of gemcitabine and dFdU concentrations in tumor tissues was 
slightly higher, but not reaching statistical significance, between the 
AsPC1+shTG2 and AsPC1+shCtrl tumors (Figure 46, n=6 per group, p = 0.4).  
This non-significant trend might be explained by high variability within the groups, 
consisting of only 6 mice.  We cannot completely exclude that TG2 knockdown 
does not alter gemcitabine penetrance into tumor tissue. 
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Figure 46.  Gemcitabine concentration in tumor tissue is not affected by TG2 
knockdown in PDA cells.  Sum of gemcitabine and dFdU concentration per tumor weight 
(ng/g) in AsPC1+shCtrl and +shTG2 xenografts (n=6 per group, p = 0.4).  Bars represent 
average quantification ± SE. 
 
 
 
 
3.15.  Knockdown of TG2 does not affect microvessel density 
As we have shown that AsPC1+shTG2 tumors respond more efficiently to 
gemcitabine compared to controls, we questioned whether delivery of 
gemcitabine was increased in shTG2 tumors altered vascularization.  To 
determine the number of vessels present in the ±shTG2 pancreatic xenografts, 
IHC staining for CD31, a marker for angiogenesis, was performed in shCtrl and 
shTG2 pancreatic xenografts.  The number of CD31 positive vessels was 
counted by a board-certified pathologist [Robert Emerson, IUSM]. 
A trend towards an increase in microvessel density (MVD) was observed 
in shTG2 tumors compared to controls (Figure 47, n=6 per group, p = 0.2), 
suggesting that perhaps tumors are better vascularized in the absence of TG2.  
However, this did not reach statistical significance and requires future validation. 
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Figure 47.  Knockdown of TG2 in PDA cells does not affect MVD in tumors.  Average of 
number of vessels counted in AsPC1+shCtrl and +shTG2 xenografts (n=6 per group, p = 
0.2).  Brown staining represents CD31+ microvessels.  Bars represent average vessel 
counts ± SE. 
 
 
 
 
 In all, our data suggest that knockdown of TG2 in PDA cells sensitizes 
tumors to gemcitabine, possibly by inducing angiogenesis and delivery of 
gemcitabine in tumor tissue.  Future studies focusing on validation of TG2-
mediated vascularization and gemcitabine penetrance in tumors are required to 
delineate mechanism by which TG2 increases tumor response to gemcitabine.  
Additionally, TG2 induced proliferation of fibroblasts in the matrix may provide a 
protective effect and favor continued tumor growth. 
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CHAPTER 4.  DISCUSSION 
4.1.  Summary of results 
Our findings outline how changes in the pancreatic cancer stroma induced 
by TG2 secreted from PDA cells alter tumor growth.  We show that 
overexpressed TG2 in PDA cells and in tumors is secreted into the culture 
medium and the tumor milieu, respectively.  TG2 secreted from PDA cells is 
catalytically active and crosslinks collagen in the matrix.  In addition, the secreted 
TG2 and the TG2-mediated crosslinked collagen activate fibroblasts, promoting 
their proliferation and increasing collagen production.  Eventually, this promotes 
tumor growth, in vivo.  These effects are abolished by TG2 knockdown with 
shRNA, which causes reduced amount of thick, crosslinked collagen and 
decreased number of active fibroblasts.  TG2 knockdown, in vivo, also inhibits 
tumor growth.  Furthermore, we showed that the fibrosis-rich stiff pancreatic 
tumors activate YAP/TAZ signaling, promoting PDA cell proliferation.  Taken 
together, these data demonstrate the effects of enzymatically active TG2 on the 
pancreatic TME and their subsequent consequences on cancer cell proliferation 
and tumor growth, supporting future studies targeting the crosslinking activity of 
TG2 to disrupt tumor progression. 
 
4.2.  TG2 expression in PDA cells and in tumors 
Previously, it has been reported that TG2 is overexpressed in epithelial 
cancers, such as ovarian and breast cancers (Condello et al., 2014; Lorand & 
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Graham, 2003; Mehta et al., 2004).  TG2 is also overexpressed in pancreatic 
cancer (Verma, Guha, Diagaradjane, et al., 2008; Verma, Guha, Wang, et al., 
2008).  
Mehta and co-workers have previously reported that, TG2 is highly 
expressed in 42 out of 75 (56%) drug resistant and metastatic human PDA 
tumors and in all of 12 human PDA cell lines analyzed (Verma et al., 2006).  
Consistent with these reports, we show abundant expression of TG2 in 36 out of 
52 (69%) PDA specimens, supporting increased TG2 expression in PDA 
compared to the normal duct epithelium.  We also show that 4 different human 
PDA cell lines express higher levels of TG2 compared to pancreatic normal 
epithelial cells.  Those 4 different cell lines expressed variable TG2 levels; 
relatively abundant TG2 in AsPC1 and BxPC3 cell lines and relatively low TG2 in 
Panc1 and Paca2 cell lines.  These differences may be due to different 
characteristics of the cells’ tumor of origin. 
We also show that TG2 is secreted in the ECM.  Similar to reports by 
Lorand and Graham (Lorand & Graham, 2003) describing that TG2 is secreted in 
the ECM and is involved in the ECM assembly, we observed abundant TG2 
localization in the ECM of PDA tumors.  This is the first report showing that TG2 
secreted from PDA cells is localized especially in the PDA stroma. 
TG2 lacks leader peptide or hydrophobic domain, which are typically 
present for secreted proteins to be exported (Gentile et al., 1991; Liu et al., 
2002).  Surprisingly, however, localization of TG2 was observed not only in the 
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cytoplasm, but also on the cell surface and extracellular space of undamaged 
endothelial and smooth muscle cells, macrophages, fibroblasts, and osteoblasts 
(Iismaa et al., 2009; Lorand & Graham, 2003).   
Some reports proposed that the externalization of TG2 occurs through 
intracellular trafficking toward the cell surface, while others suggested that it is 
mediated through interaction with other transmembrane proteins, such as 
integrins or adrenergic receptors (Lorand & Graham, 2003), or with extracellular 
binding partners, such as fibronectin and heparin sulfate proteoglycans (Gaudry 
et al., 1999; Scarpellini et al., 2009).  Belkin et al. has proposed that TG2 
externalizes through trafficking of perinuclear recycling endosomes, which 
requires initial tethering of TG2 to endosomal phosphoinositides, subsequent 
tight binding to endosomal membrane, and fusion with plasma membrane 
(Belkin, 2011).  In addition, Belkin et al. have shown that this secretion can be 
inhibited by nitric oxide, which is involved in angiogenesis (Santhanam et al., 
2011).  However, the mechanism of TG2 secretion across lipid bilayers of 
membrane remains disputed. 
 
4.3.  TG2 activity in the PDA stroma 
 It is known that the functions of TG2 are tightly controlled by 
environmental factors that cause allosteric structural changes and alter the 
accessibility of the catalytic domain.  High Ca2+ concentrations in the ECM allow 
the protein to adopt an open conformation that exposes the catalytic core, while 
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high intracellular GTP forces a closed, enzymatically inactive structure (Pinkas et 
al., 2007).  These conformational changes suggest that TG2 should be 
catalytically inactive in the intracellular environment under normal physiological 
conditions. 
However, here we show that TG2 is enzymatically active in the pancreatic 
TME based on analyzes testing incorporation of 5-BP and T26 small peptides.  5-
BP is a biotinylated amine, which gets incorporated onto glutamine residues on 
accessible TGase substrates.  T26 is a FITC-labeled glutamine donor substrate 
specific for TG2.  In the presence of catalytically active TG2, both 5-BP and T26 
are crosslinked and incorporated in proteins harboring free amine groups.  Here 
we showed that TG2 is catalytically active in PDA cells and in the stroma where it 
crosslinks collagen, and possibly other ECM substrates.   
However, we did not detect 5-BP incorporation in human dermal 
fibroblasts and T26 incorporation in mesothelial LP9 cells under normal 
physiological conditions, suggesting that TG2 is enzymatically inactive in these 
normal cells.  On the other hand, incorporation of 5-BP was detectable in the 
cytoplasm and on the membrane of PDA cells.  TGase activity was inhibited by 
EDTA, a Ca2+ chelator that is known to inhibit the catalytic activity of TGases.  In 
addition, incorporation of T26 into proteins in the cytoplasm and on the 
membrane of PDA cells was observed, confirming that TG2 is enzymatically 
active in malignant PDA cells.  However, under low intracellular Ca2+ and high 
GTP concentrations, TG2 should be catalytically inactive.  Our findings showing 
intracellular TG2 crosslinking activity inside cancer cells suggest that the enzyme 
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may be abnormally activated in transformed cells.  The factors causing TG2 
activation within PDA cells remain not known and future studies are needed to 
delineate the mechanism. 
In situ TG2 activity was also detected in pancreatic xenografts by using 
the T26 assay.  T26 incorporation was observed both intra- and extra-cellularly in 
AsPC1 and Panc1 xenograft sections, supporting that secreted TG2 from PDA 
cells is enzymatically active in the tumor milieu.  Khosla’s group previously 
reported that extracellular TG2 is enzymatically inactivated through oxidation, 
which forms disulfide bonds between Cys370 and Cys371 residues.  Reducing 
factors, such as dithiothreitol (DTT) and thioredoxin (Trx), are required to restore 
TG2 enzymatic activity (Jin et al., 2011). 
To exclude the possibility that TG2 may be activated spuriously in this 
assay, we carried out the assay in the absence of DTT.  We still observed 
incorporation of T26 in the ECM in the absence of DTT in the reaction solution, 
supporting that TG2 is enzymatically active in situ in these tissues.  We do not 
know whether other reducing factors are endogenously present in the pancreatic 
milieu and could cause TG2 activation.  Further studies are needed to elucidate 
the observed phenomenon.  
 In addition to that report, they also reported that extracellular TG2 is 
catalytically inactive, but can be transiently activated upon tissue injury (Siegel et 
al., 2008).  Therefore, it is tempting to speculate that tissue injury including 
hypoxia inflicted by tumorigenesis may be inducing TG2 enzymatic activity in vivo 
   110 
(Filiano, Bailey, Tucholski, Gundemir, & Johnson, 2008).  In addition, metabolic 
or physical factors involved in oxidative stress and Ca2+ homeostasis, for 
example, may be expressed or function differently in transformed compared to 
normal cells.  Interestingly, a previous report by Verma et al. suggested that IκBα, 
the NF-ĸB inhibitory subunit, is a direct substrate of TG2 enzymatic activity in 
PDA cells (Verma et al., 2006), although direct evidence of TG2 activity was not 
provided in that report.   
 
4.4.  Stromal alterations induced by TG2 
The ECM of the pancreatic stroma is prominently composed of collagens, 
non-collagen glycoproteins, growth factors, and modulators of the cell-matrix 
interaction (Duner, Lopatko Lindman, Ansari, Gundewar, & Andersson, 2010; 
Feig et al., 2012).  Among prominent ECM proteins, collagen I, III, and fibronectin 
are the major components of the pancreatic DS (Gress et al., 1995; Lunardi et al., 
2014; Mahadevan & Von Hoff, 2007), and they are potential substrates for TG2. 
Here we also show that collagen I, a known TG2 substrate, was 
crosslinked by TG2 leading to the formation of a dense matrix in the pancreatic 
milieu.  TG2 expressing PDA cell-derived pancreatic xenografts contained higher 
proportion of thick, crosslinked collagen, lesser amount of soluble, non-
crosslinked collagen, and the same amount of total collagen compared to shTG2 
xenografts, confirming that TG2 secreted by PDA cells into the tumor milieu 
crosslinks collagen, making it stable and insoluble.  
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In addition, we showed that the TG2-mediated crosslinked collagen 
promoted the growth of fibroblasts.  Proliferation of fibroblasts, in vitro, was 
induced by native collagen and furthermore by TG2-mediated crosslinked 
collagen.  We also showed that TG2 expressing PDA cells promoted the growth 
and the activation of fibroblasts.  Co-culture of fibroblasts with TG2 expressing 
PDA cells increased activation, proliferation, and collagen deposition of the 
fibroblasts compared to the co-culture with TG2 KD cells.  Likewise, higher 
content of active fibroblasts (α-SMA positive) was detected in the control 
pancreatic xenogragfts compared to shTG2 xenografts.  Our findings are 
consistent with a previous report demonstrating that collagen crosslinked by TG2 
stimulated the proliferation of dermal fibroblasts (Chau et al., 2005) and with 
studies demonstrating the involvement of TG2 in wound healing and in 
pathologic fibrotic responses in the lung or liver (Collighan & Griffin, 2009; Olsen 
et al., 2014; Olsen et al., 2011; Shweke et al., 2008; E. A. Verderio, Johnson, & 
Griffin, 2004). 
We also showed that these alterations of collagen and fibroblasts 
conversely stimulated the growth of PDA cells.  Proliferation of PDA cells was 
promoted when cells were grown on collagen vs. no collagen and on feeder layer 
of hPSCs vs. no hPSCs.  In addition, higher PDA cell proliferation rate, as 
measured by Ki67 staining, was detected in vivo in the TG2 expressing cell-
derived pancreatic xenografts compared to shTG2 xenografts. 
In contrast, knockdown of TG2 in PDA cells did not alter their proliferation 
and clonogenic potential, in vitro.  These findings suggested that the effects of 
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TG2 on tumor growth are not explained by direct effect on cancer cells, but by 
TG2-mediated alterations of the stroma, which in turn regulate tumor 
progression. 
In contrast to the activation and proliferation of fibroblasts observed in the 
co-culture with TG2 expressing PDA cells, addition of active recombinant TG2 
did not affect the proliferation of the fibroblasts.  This finding suggests that TG2 
acts in concert with other factors secreted in the ECM. 
Taken together, our findings demonstrate that PDA cells secreting TG2 in 
the tumor milieu promote fibroblast activation and proliferation as well as 
collagen crosslinking, leading to stromal alterations, which in turn promote tumor 
growth. 
In addition to our findings, we suspect that the enzyme has other 
substrates in the pancreatic ECM and that their modifications through 
crosslinking could contribute to the distinct architecture of the DS, which in turn 
fosters tumor progression.  
To sum up, we report a significant decrease in the number of activated 
myofibroblasts and thick collagen fibers in tumors derived from shTG2 
transduced cells, and show that these stromal alterations directly affect 
proliferation of fibroblasts and cancer cells.  The protective role of the pancreatic 
stroma to cancer cells has been previously recognized and linked to the 
resistance of pancreatic tumors to chemo and radiotherapy (Erkan, 2013; 
Garrido-Laguna et al., 2011; Gore & Korc, 2014).  Our data implicate for the first 
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time TG2 as a modulator of the pancreatic TME through its protein crosslinking 
properties.   
 
4.5.  TG2 promotes pancreatic tumor growth 
Here we demonstrate that TG2 knockdown by shRNA in pancreatic 
cancer cells inhibits tumor growth.  We showed decreased average volume and 
weight of shTG2 tumors compared to control tumors.  This result is consistent 
with a previous study reported by Mehta and colleagues (Verma, Guha, 
Diagaradjane, et al., 2008).  They used TG2-specific siRNA-DOPC liposome to 
knockdown TG2 in an orthotopic mouse model.  The siRNAs were delivered via 
intravenous injection, and this led to inhibition of pancreatic tumor growth along 
with decreased tumor vascularity (Verma, Guha, Diagaradjane, et al., 2008). 
However, in contrast to their report, we did not observe changes in multi-
vessel density between TG2 expressing and TG2 knockdown tumors.  This 
contradictory result may have resulted from different approaches in TG2 
knockdown.  Non-specific delivery of siRNA targeting TG2 via intravenous route 
in their model may have affected all TG2 expressing cells (including endothelial 
cells), while TG2 knockdown was restricted to PDA cells in our model.  Therefore, 
it is possible that TG2 knockdown in endothelial cells in their model led to the 
anti-angiogenic effect observed.  
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4.6.  TG2 induces YAP activation in PDA cells 
Here we link for the first time TG2 to activation of the transcriptional 
regulators, YAP and TAZ, in cancer cells.  YAP/TAZ are known transcription 
factors involved in the Hippo signaling pathway, a pathway strongly implicated in 
cell survival and proliferation and activated in epithelial cancers (Cordenonsi et 
al., 2011; Zeng & Hong, 2008).  Independent of the canonical Hippo signaling 
pathway, YAP/TAZ can be regulated by the physical properties of the ECM and 
are involved in mechanotransduction, translating mechanical cues into relevant 
biological signals (Dupont et al., 2011).  Recent reports have implicated YAP 
activation in pancreatic tumor progression downstream or independent of mutant 
Kras (Kapoor et al., 2014; Zhang et al., 2014).  Zhang et al. reported that 
pancreas-specific deletion of YAP in mutant Kras (KrasG12D) mice inhibited the 
progression of neoplastic PDA lesion to PDA, and that YAP is an important 
transcriptional factor downstream of Kras/MAPK signaling pathway, promoting 
neoplastic cell proliferation of PDA progression (Zhang et al., 2014).  In addition, 
Kapoor et al. reported that overexpression of Yap1 induces PDA recurrence 
independent of Kras mutation and MAPK signaling pathway by forming a 
Yap1/Tead2 complex that interacts with E2F transcriptional factor, resulting in 
activation of cell cycle and DNA replication (Kapoor et al., 2014).  Here we 
propose that the pancreatic matrix rendered denser by TG2 through collagen 
crosslinking and stimulation of a fibrotic response provides positive proliferative 
feedback to the cancer cells by stimulating YAP/TAZ signaling.  
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We show that the matrix, specifically collagen, activates YAP/TAZ in PDA 
cells leading to their nuclear localization and induces target gene (CTGF) 
expression.  In addition, nuclear localization of YAP/TAZ correlates with TG2 
expression level in PDA cells.  Higher intensity of nuclear YAP/TAZ was detected 
in TG2 expressing control PDA cells compared to TG2 knocked-down cells, and 
in abundant-TG2 expressing cells (AsPC1) compared to low-TG2 expressing 
(Panc1) cells.  We speculate that these effects may have resulted from stimuli 
triggered by the stiff collagen matrix, crosslinked by secreted TG2 from PDA cells.  
However, a limitation of our study is that we were not able to measure the actual 
mechanical forces of the matrix.  Therefore, we cannot exclude that signals other 
than tissue stiffness, directly modulated by TG2 or by the matrix, contribute to 
YAP activation.  Future studies should be performed to determine the stiffness of 
the tumor and the collagen matrix in the presence of TG2 or when TG2 is 
inhibited. 
In addition, we show that knockdown of YAP/TAZ in PDA cells grown on 
collagen correlates to decreased cell proliferation, suggesting that YAP/TAZ are 
directly involved in regulation of PDA cell proliferation. 
Collectively, our findings outline a new mechanism by which PDA cell 
proliferation is modulated by TG2 through signals reflected from the tumor into 
the surrounding stroma (Figure 48). 
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These observations led us to propose that the stimulatory growth signals 
conveyed by TG2 require the stroma, which “deflects” mechanical or biological 
cues from the tumor milieu into an active oncogenic program.   
 
 
 
Figure 48.  Proposed mechanism by which TG2 promotes tumor growth.  TG2 
expressed and secreted by PDA cells in the tumor microenvironment modulates the 
stroma by activating stromal cells and crosslinking collagen, resulting in a fibrosis-rich 
stroma.  This dense stroma protects PDA cells from gemcitabine and activates YAP/TAZ 
in PDA cells, promoting cell proliferation and tumor growth. 
 
 
 
 
4.7.  Effect of TG2 on gemcitabine response in PDA cells and in tumors: 
Here we show that the TG2-mediated desmoplasia of the PDA stroma 
limits the gemcitabine effect.  Treatment of mice bearing AsPC1+shCtrl or 
AsPC1+shTG2 xenografts with gemcitabine significantly decreased the average 
tumor volume and weight compared to PBS (control) treatment.  In addition, 
gemcitabine treatment significantly decreased the average tumor volume and the 
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weight of AsPC1+shTG2 xenografts compared to AsPC1+shCtrl xenografts, 
suggesting that knockdown of TG2 enhanced sensitivity of tumors to gemcitabine, 
possibly by diminishing the desmoplasia of the stroma.  Our findings are 
consistent with a previous report by Verma et al. showing that siRNA-mediated 
knockdown of TG2 inhibited PDA tumor growth and enhanced gemcitabine 
therapeutic efficacy (Verma, Guha, Diagaradjane, et al., 2008). 
We also show that gemcitabine treatment of mice bearing AsPC1+shTG2 
xenografts significantly decreased number of metastases compared to the PBS 
treatment, while there was no effect of gemcitabine treatment on number of 
metastases in the mice bearing AsPC1+shCtrl xenografts.  Interestingly, 
metastatic propensity was not inhibited by TG2 knockdown alone, but 
gemcitabine treatment in addition to TG2 knockdown showed synergistic effect in 
decreasing the number of metastases in the tumor bearing mice.  These findings 
may be related to less fibrotic stroma due to TG2 knockdown, which in turn 
provides improved penetrance of gemcitabine. 
Our findings demonstrating decreased metastatic propensity of the 
combination of TG2 knockdown and gemcitabine treatment is consistent with the 
previous report by Verma et al. (Verma, Guha, Diagaradjane, et al., 2008).  
However, we were not able to show inhibition of metastasis only by knockdown 
of TG2 in PDA cells, while the other authors have observed dramatic decrease in 
metastasis by TG2 knockdown alone.  As mentioned earlier, this difference may 
have resulted as a consequence of the different approaches of TG2 
downregulation, which nonspecifically affected TG2 expression in their model 
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leading to anti-angiogenic effects and the subsequent inhibition of cell 
proliferation, tumor growth, and metastasis. 
In addition, and in contrast to their results, we did not observe changes in 
microvessel density between TG2 expressing and TG2 knockdown tumors.  This 
indicates not only that restricted TG2 knockdown in PDA cells is not sufficient to 
alter angiogenesis in PDA tumors, but also that enhanced gemcitabine effect in 
the shTG2 tumors is not related to altered delivery of the drug through vessels. 
Here we also show that uptake of gemcitabine in AsPC1+shCtrl and 
AsPC1+shTG2 xenografts, 2 minutes after intravenous administration, is not 
significantly different.  This may have resulted from similar microvessel density 
between the shCtrl and the shTG2 tumors, which contributed to the same 
delivery of gemcitabine into tissues. 
  However, even though the gemcitabine concentrations between the two 
groups were not statistically significant, there was a trend of higher gemcitabine 
concentration in shTG2 tumors.  As tumors were harvested only 2 minutes after 
one dose of gemcitabine administration, some variability in gemcitabine tissue 
distribution may have occurred.  In addition, only 6 mice per group were used for 
this study.  As in vivo experiments with mice have high variability, increasing the 
number of specimens could decrease the observed variability.  
In vitro, we also show that knockdown of TG2 in PDA cells itself does not 
significantly affect sensitivity to gemcitabine.  However, PDA cells in a co-culture 
with fibroblasts were protected from gemcitabine treatment compared to the PDA 
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cells cultured alone.  These findings indicate that the dense, fibrotic stroma 
resulting from the TG2-mediated activate fibroblasts and crosslinked collagen 
may be linked to chemoresistance in pancreatic cancer.  This stroma protects 
PDA cells from gemcitabine and promotes continuous proliferation of PDA cells 
and tumor growth.   
Taken together, this is the first report describing the effects of TG2 on the 
pancreatic TME, and its subsequent consequences on cancer cell proliferation 
and tumor growth.  Our study demonstrates that TG2 expressing PDA cells form 
larger pancreatic tumors, enriched in thick collagen fibers and in active 
fibroblasts.  The dense stroma of TG2 expressing PDA tumors protects PDA 
cells from gemcitabine and conveys signals leading to YAP/TAZ activation in 
cancer cells promoting cell proliferation and tumor growth (Figure 48).  Our 
findings support the involvement of enzymatically active TG2 in the progression 
of PDA and future studies targeting the crosslinking activity of TG2 to disrupt 
tumor progression. 
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CHAPTER 5.  FUTURE DIRECTIONS 
 The 5-BP and T26 incorporation experiment showed that TG2 is 
enzymatically active only in PDA cells but not in the normal fibroblasts and 
mesothelial cells.  However, the factors causing TG2 activation within PDA cells 
remain unknown.  Therefore, future studies are needed to delineate the 
mechanism. 
 In addition, we hypothesized that stiffness of the collagen matrix leads to 
activation of YAP and TAZ in PDA cells grown on collagen.  However, a limitation 
of our study was that the actual mechanical forces of the matrix could not be 
measured.  Therefore, we cannot exclude that signals other than tissue stiffness, 
directly modulated by TG2 or by the matrix, contribute to YAP activation.  Future 
studies are required to determine the stiffness of the tumor and the collagen 
matrix in the presence or knockdown of TG2. 
In this study, we focused on the involvement of TG2 in the alteration of 
collagen and stromal cells in the tumor milieu.  However, as the pancreatic 
stroma is heterogenous with various cytokines, growth factors, and extracellular 
matrix proteins, it is possible that other factors in the ECM may be involved in 
modulation of PDA stroma leading to tumor progression and chemoresistance.  
Therefore, future studies are needed to identify other factors involved in the 
stroma alteration in concert with TG2. 
Lastly, effects of TG2 enzymatic inhibitors on tumor progression and 
response to chemotherapy will be explored. 
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